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The total synthesis of natural (+)-hyacinthacine C5 was achieved, which allowed correction of 
its initially proposed structure, as well as six additional hyacinthacine C-type compounds. 
These compounds were readily accessible from two epimeric anti-1,2-amino alcohols. 
Keeping a common A-ring configuration, chemical manipulation occurred selectively on the 
B-ring of the hyacinthacine C-type products through methods of syn-dihydroxylation, SN2 
ring-opening of a cyclic sulfate and also employing either (R)- or (R,S)-α-methylallyl amine 
for the Petasis borono Mannich reaction. Our small analogue library was then assessed for its 
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glycosidase inhibitory potency against a panel of glycosidases. (–)-6-Epi-hyacinthacine C5 
and (+)-7-epi-hyacinthacine C5 (compound names are based on the corrected structure of 
hyacinthacine C5) proved most active, with inhibitory activities ranging between weak (IC50 = 
130 µM) to moderate (IC50 = 9.9 µM) against the α-glucosidases of rat intestinal maltase, 
isomaltase and sucrase, thus identifying potential new leads for future antidiabetic drug 
development. 
INTRODUCTION 
Owing to their considerable glycosidase inhibitory activities, research towards the isolation of 
polyhydroxylated alkaloids (PA) within water soluble plant extracts has led to the relatively 
recent discovery and increased interest of the polyhydroxylated 3-hydroxylmethyl 
pyrrolizidine natural products, otherwise known as the hyacinthacine alkaloids.
1–6
 To date, 
nineteen hyacinthacine alkaloids of general structure 1 (Figure. 1) have been isolated from 
extracts of the Hyacinthaceae family and fourteen of these hyacinthacine alkaloids have been 
the subject of total synthesis.
6–15
 Additionally, different methods have also been employed 
towards the synthesis of many unnatural hyacinthacines, increasing the scope and potential 
finding of more potent analogues to be used as possible antiviral, anticancer, antidiabetic and 
anti-obesity drugs.
16,17
 The current classification system for hyacinthacine alkaloids divides 
these compounds into the following: hyacinthacines A1-7, B1-7, and C1-5; whereby the letter 
assignment, A, B or C, corresponds to the presence of 0, 1 or 2 hydroxy/hydroxymethyl, 
substituents found on the B ring, respectively (Figure 1).
18–21
 Regardless of whether a natural 
isolate or synthetically derived, structures and relative configurations have been assigned 
through NMR spectroscopic and MS spectrometric analysis with the only X-ray 
crystallographic data pertaining to the later classified compounds.
10,15
 With no current X-ray 
crystallographic structures of the natural isolates, total synthesis is the only way to 
confidently confirm or revise the relative and absolute configuration of these alkaloids. 
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Hyacinthacine C-type alkaloids have generated much interest as they contain at least six 
stereogenic centers and so excluding all possible enantiomeric relationships, there are 64 
unique possible diastereomers of a 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7-tetraol, 
each potentially offering specific glycosidase inhibition. As a result of this structural 
complexity however, they are often difficult to stereochemically define (Figure 1). To date, 
only the structure of hyacinthacine C2 has been confirmed by total synthesis.
14
 Structural 
validation for hyacinthacine C1 and C4 is needed since both have been attributed identical 
structures (2 and 5, Figure 1), yet contain different NMR spectroscopic data.
18,21
 Furthermore, 





 are incorrect. Synthetic C-type hyacinthacines are important not only to confirm 
these natural structures, but to also provide compounds that are highly structurally analogous 
to glucose which offer greater potential as drugs to treat diabetes and obesity.  
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Figure 1. General structure of the hyacinthacine C-type alkaloids 1, including the 
hyacinthacine C-type alkaloids 2-6 isolated so far. Highlighted are the identical structures 




Much synthetic work has focused on unambiguously establishing the correct structure of (+)-
hyacinthacine C5. In 2011, the proposed structure of hyacinthacine C5 (6) was reported to be 
incorrect, as Yu and colleagues accessed the hyacinthacine pyrrolizidine core after employing 
a Cope-House cyclization to make the enantiomeric structure, (–)-hyacinthacine C5.
15
 Later 
that year, Tamayo et al. synthesized the putative (+)-hyacinthacine C5 6 (Figure 1), using a 
chiral pyrrolidine as the basis for the stereogenic centers on ring-A, followed by an non-
selective dihydroxylation reaction.
23
 This synthetic work provided further supporting 
evidence that the initial isolate from 2007 was structurally incorrectly assigned. Since then, 
only one other synthetic route to the structure of 6 (Figure 1) has been employed by Reissig 
and Goti et al. through 3-methyl-substituted alkoxyallenes, in which their divergent pathway 
resulted in the synthesis of (–)-hyacinthacine B4, the originally proposed structure of (+)-
hyacinthacine C5 (6) and its C5-epimer, again supporting the incorrect stereoconfiguation of 
the natural product.
22
 Their findings in combination with a reassessment of the NMR 
spectroscopic data from the original isolation paper lead them to hypothesize that the natural 
hyacinthacine C5 isolate is actually (+)-1-epi-hyacinthacine C4 7 (Figure 2).  
To therefore broaden the scope and accessibility of the hyacinthacine C5 pyrrolizidine core, 
we herein report the synthesis of the originally proposed structure of (+)-hyacinthacine C5 6, 
along with its revised structure 7 (Figure 2) (It should be noted that compound names used 
throughout this section are in reference to the corrected structure of hyacinthacine C5 (7)). In 
addition to this, our synthetic strategy has allowed five epimers of hyacinthacine C5, 8, 9, 10, 
11 and 12 (Figure 2) to be prepared and biologically evaluated to gain a better understanding 
of their structure-activity relationships as glycosidase inhibitors. 
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Figure 2. The 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7-tetraol common core (red) to 
each of the structures of our synthetic target hyacinthacine C-type alkaloids 6-12. Compound 
names are related to natural hyacinthacine C5 (7) 
 
RESULTS AND DISCUSSION 
As the highlighted (red) 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7-tetraol shows in 
Figure 2, each of the hyacinthacine targets (6-12) in this study share common stereogenic 
centers at C1, C2, C3 and C7a. By fixing the configurations of the 1, 2, 3 and 7a stereocenters 
(i.e., all those associated with the A-ring), the number of possible diastereomers synthesized 
is reduced from 64 to a sub-class of 8, where in this study, seven of these eight have been 
prepared. A retrosynthetic analysis shown in Scheme 1 suggests that the diol configuration at 
C6 and C7 in A can be manipulated at a later stage and will allow access to compounds 6-12. 
The key intermediate to all seven target molecules would be the Petasis borono Mannich 
reaction product C.
24–28
 This reaction delivers five of the seven stereogenic centers of the 
target molecules via the three component reaction of the protected L-xylose 13, and two 
commercially available precursors; either (R)- or (S)-α-methylallyl amine·HCl 14 and trans-
2-phenylvinyl boronic acid 15 (Scheme 1).  
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Scheme 1. Retrosynthetic analysis of targets 6-12 
 
 
Synthesis of 8, 9 and 11. 
The C6, C7 syn-B-ring diol hyacinthacine analogues 8, 9 and 11 were synthesized initially to 
help establish access to the hyacinthacine C5 pyrrolizidine core. Preparation towards this is 
shown in Scheme 2 through the synthesis of the literature established L-xylose derivative 13 
as starting material in 76% yield over three steps from L-xylose.
29–31
 Compound 13 was 
treated with commercially available, and enantiomerically pure (R)-α-methylallyl amine·HCl 
14 and trans-2-phenylvinyl boronic acid 15 under Petasis boronic acid Mannich reaction 
conditions in EtOH to provide a single diastereomer of the anti-amino diol 16 in 65% 
yield.
26,27
 Whilst spectroscopic analysis confirmed the formation of 16, it was found that the 
HCl salt of 16 was highly crystalline
32
 and so X-ray crystallographic studies were then used 
to confirm the anti-stereochemical outcome of the newly formed 1,2-amino alcohol. This 
configuration was expected based on mechanistic considerations and the anticipated reactive 
intermediate D in which 1,3-allylic strain between the substituents at the α-position and on 
the N-atom of the iminium ion are minimized.
12,13,26
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With our advanced intermediate 16 in hand, our attention focused on protecting the secondary 
amine, since if left unprotected could potentially coordinate to the Ru catalyst used in a 
subsequent ring-closing metathesis (RCM) reaction, inhibiting formation of the pyrrolizidine 
B-ring.
13
 To achieve this, we envisioned preparation of the 4,5-disubstituted oxazolidinone 
derivative of 16 as this would simultaneously protect the secondary amine and also enable us 
to verify the relative stereochemistry of stereocenters C4 and C5 in the parent and 
oxazolidinone products.
33–37
 Our initial attempts to protect the amino group of 16 with 
triphosgene/Et3N returned a mixture (1 : 2, respectively) of the oxazolidin-2-one 17 and the 
oxazepin-2-one 18 (37% yield, Scheme 3(a)). Pure samples of 17 and 18 could be obtained 
for analytical purposes, but their efficient separation at preparative scale was difficult. Since 
separation of the mixture of 17 and 18 was not practical, facile migration of the carbonyl of 
18 to give 17 was considered.
38
 For a clean migration to the thermodynamically more stable 
oxazolidinone 17, stirring the mixture in methanol with a stoichiometric amount of DBU at 
room temperature for 4 h proved to be the most effective conditions, achieving a quantitative 
conversion to 17 (Scheme 3(a)). The 7.1 Hz vicinal coupling constant J4,5, in the 
1
HNMR 
spectrum of 17, was consistent with the 4,5-cis relative configuration.
35–37
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Although an interesting finding, it was also found that 16 could also be protected with di-tert-
butyl carbonate to give the N-Boc derivative 19 in 62% with 23% recovered starting material 
16 (Scheme 3(b)). Base-induced (NaH, THF) conversion to the oxazolidinone 17 (85% yield, 





Scheme 3. Synthesis of oxazolidinone 17, oxazepinone 18 and N-Boc protected 19 
 
 
A Ru-catalyzed RCM reaction of 17 using 5 mol% Grubbs’ second-generation catalyst 
afforded compound 20 in high yield (Scheme 4). This reaction had to be monitored carefully 
(TLC analysis) as the alkene group in 20 was prone to migration under extended reaction 
times to give an inseparable mixture of olefin containing species. The RCM product 20 was 
then subject to a Upjohn Os(VIII)-catalysed syn-dihydroxylation (DH) reaction
42
 and 
provided two diastereomeric diols 21a (major) and 21b (minor) in 75 % (dr = 3:1 of the 
crude reaction mixture) (Scheme 4). Only small amounts of pure diols 21a and 21b could be 
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separated by flash column chromatography (FCC), and so it was fortunate that clean 
conversion of the diastereomeric mixture to the acetonides 22 and 23 (respectively, Scheme 
4) accentuated the Rf difference between the diastereomers allowing for easier separation by 
FCC. The major diastereomer 22 was expected to result from syn-dihydroxylation to the 
alkene face of 20 that was anti to the C5 methyl substituent due to steric directing effects. 
Extensive ROSEY NMR analysis of 22 found key correlations between H1՛ ՛ ‒H8a, H1՛ ՛ ‒
3a, H8a‒H3a, H8‒H3b and H3b‒H4 (Figure 3) which were consistent with the assigned 
configurations. In comparison, 1D NOE difference studies on 23 showed NOE enhancements 
between H8‒H8a, H8‒H3a, H8a‒H3a, H3a‒H3b and H3b‒H4 (Figure 3). These were 
consistent with the structure assigned to 23.  
 
Scheme 4. Synthesis of acetonides 22 and 23  
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Figure 3. Experimental ROSEY (22) and 1D NOE difference (23) NMR correlations 
projected onto DFT minimized molecular models (B3LYP/6-31G(d)) of acetonides 22 and 23 
(C4 alkyl chain not shown) 
 
 
Acetonides 22 and 23 were then separately subject to base hydrolysis under microwave 
heating conditions to give their respective amino diols 24 and 25 in overall high yields 
(Scheme 5).  
 


















MW, 110 oC,1 h
NaOH, EtOH




Based on our previous work, furnishing the pyrrolizidine core from similar amino alcohols 
have employed treatment with a stoichiometric amount of MsCl under basic conditions 
(Et3N).
10,12,13
 This method was employed for both amino diols 24 and 25 (Scheme 6 (a)). 
Shown in Scheme 6 (a) and via intermediate A, the proposed mesylation-cyclisation of 24 
afforded only a 30 % yield of the pyrrolizidine 26. Interestingly, the N,O-dimesylated adduct 
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Despite the impact on the yield of the desired product, a single-crystal X-ray structural 
analysis of 24a allowed confirmation of the stereochemical assignments made to 22. 
Fortunately, employing Appel cyclization reaction conditions
43
 overcame this problem, 
affording the same pyrrolizidine 26 in 87 % yield (Scheme 6 (b)). In stark contrast, 
mesylation, then heat-induced cyclisation of 25 proved extremely regio-selective, returning 
product 27 in high yield (87 %) (Scheme 6 (c)). Individual samples of 26 and 27 were then 
globally deprotected under hydrogenolysis conditions
44
 using PdCl2/H2 to return 8 
([α]
+5.4 (c 1.00, H2O)) (Scheme 6 (b)) and 9 ([α]
-7.2 (c 1.00, H2O)) (Scheme 6 (c)) in 
good to high yields (87 % and 98 %, respectively), following purification and neutralization 
by basic ion-exchange chromatography.  
Scheme 6. Synthesis of hyacinthacine C-type compounds 8, and 9 
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With a synthetic route to the hyacinthacine C-type core established, we next focused our 
attention towards synthesizing the 5β-methyl analogue 11. This required the use of (S)-α-
methylallyl amine·HCl in the Petasis borono Mannich reaction. Due to the unavailability of 
commercial (S)-α-methylallyl amine·HCl at the time, we employed the readily synthesized 
racemic α-methylallyl amine·HCl.
45
 This was then reacted with 13 and trans-2-phenylvinyl 
boronic acid 15 using the same conditions we employed for the synthesis of 16, affording an 
approximate 1:2 mixture of diastereomers 16 and 28 (Scheme 7). This result indicated some 
degree of kinetic preference for the reaction of the iminium ion intermediate arising from the 
(S)-enantiomer of the amine component. Finding the N-Boc-protective pathway to be 
unfeasible, the diastereomeric mixture was instead subject to triphosgene/Et3N conditions, 
where unsurprisingly, an inseparable mixture of two oxazolidinones and two oxazepinones 
was obtained in an overall yield of 43 %. Unfortunately, the ratio of these four products could 
not be determined due to extensive overlap of 
1
H NMR signals and so this mixture was 
subject to our earlier established conditions (Scheme 3) for facile migration of the carbonyl 
group, returning a clean, however inseparable, 1:2.5 mixture of oxazolidinone 17 and its 
(1՛ S)-epimer 29 as confirmed by 
1
H NMR analysis. This mixture was then treated under 
RCM reaction conditions using 5 mol% Grubbs’ second-generation catalyst, affording the 
separable bicyclic alkenes 20 and 31 in 27 % and 53 % yields, respectively. Fortunately, the 
rigidity in both bicyclic structures was profound enough to provide a significant difference in 
Rf values for each isomer allowing their easy separation using FCC, whereby spectroscopic 
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Scheme 7. Synthesis of RCM products 31 and 20 
 
 
Treatment of 31 using the same DH conditions as described in Scheme 4 produced a single 
diastereomer 32 (98 %) which was subsequently converted to the acetonide 33 (98 %) 
(Scheme 8). Although subject to extensive NMR spectroscopic analysis, the configuration of 
the syn-diol at C8a and C3a as well as the configurations for their pre-cursor compounds, 28, 
29, 30 and 31, was unequivocally determined by single-crystal X-ray studies of both the 
parent diol 32 and the resultant acetonide 33.
32
 Base hydrolysis of acetonide 33 gave the 
amino diol 34, followed by treatement with 1 eq. of methanesulfonyl chloride and heating at 
reflux in DCE for 20 h furnished the pyrrolizidine 35 in 76 % yield. Similar to the 
pyrrolizidine synthesis of 25, the high yield of pyrrolizidine 35 suggested a highly regio-
selective O-mesylation. Global deprotection of pyrrolizidine 35 first removing the acetonide 
under acidic conditions to give pyrrolizidine 36, then using PdCl2/H2 followed by purification 
via ion-exchange chromatography, returned the hyacinthacine C-type analogue 11 ([α]
-6.9 
(c 1.00, H2O)) (Scheme 8) which was found to be the enantiomer of the hyacinthacine C-type 
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+4.3 (c 0.35, H2O)) synthesized by Yu et al. in 2011.
15
 When compared 
with Yu’s synthesized compound, our synthetic 11 was a close match in both the 
1
H NMR 
(∆δH = 0.9-0.22 ppm) and 
13
C NMR (∆δC = 0.4-1.4 ppm) spectroscopic data (see Table S3 and 




Scheme 8. Synthesis of 11 
 
 
Synthesis of 6, 7, 10 and 12. 
At this stage, none of our synthetic hyacinthacine C-type molecules (8, 9, and 11) matched 
spectroscopically with the natural isolates for hyacinthacine C1, C4, or C5 and so our attention 
focused on synthesizing the more complex anti-6,7-diol B-ring series. Our initial target was 
to synthesize the proposed structure of hyacinthacine C5 6. As our retrosynthetic analysis 
(Scheme 1) suggests, selectively inverting stereogenic centers at C6 and C7 of the 
pyrrolizidine core via Sharpless cyclic sulfate chemistry
46
 could be a possibility if the A-ring 
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hydroxyl groups were suitably protected. We recognized that pyrrolizidine 35 was two 
potential steps away from this envisioned core structure and so employing the O-benzyl 
protection using conditions established for the protection of 13, we successfully protected the 
free hydroxyl group at C8 of pyrrolizidine 35 to give 37 (Scheme 9). Acid hydrolysis of the 
acetonide of pyrrolizidine 37 revealed the syn-diol 38, which upon conversion to the cyclic 
sulfate 39, underwent subsequent ring opening with CsOBz (prepared in situ from CsCO3 and 
BzOH), returning regioisomers 40 and 41 in isolatable yields of 61 % and 12 %, respectively 
from 38. The regio- and stereochemistry of 40 was determined through observed correlations 
from both gCOSY and ROSEY NMR analysis. More specifically, it was observed that the 
resonance for the proton sharing the stereogenic carbon with the newly added benzoate 
proved the most deshielded and characteristically appeared slightly above δH 5.0 ppm. 
Analysis of the gCOSY of 40 found a strong correlation between H1'' (δH 1.24 ppm) and H5 
(δH 3.21 ppm), which was subsequently found to correlate with H6 (δH 3.94 ppm). The H6 
correlation with the lone triplet resonance at δH 5.13 ppm (otherwise H7), clearly indicated 
that the benzoate group was at C7 as opposed to C6. With the regio-chemistry established, 
our focus turned to confirming the stereoconfiguration of the SN2 inversion induced by the 
benzoate anion at C7. Consulting the ROSEY experiment for 40, we noted a relatively 
weaker correlation between H6‒H7 than that observed between H6‒H7 in the parent diol 38, 
whilst the H1''‒H6 relationship proved a strong correlation, and so suggested successful 
inversion at C7. Similarly, the gCOSY analysis of compound 41 identified H5 to strongly 
correlate with the doublet resonance at δH 5.31 ppm, which was logically assigned H6. 
Although the ROSEY analysis showed a weak correlation between H6‒H7, it was 
undoubtedly found that the correlation between H5‒H6 was of stronger intensity. Upon 
individual hydrolysis of the benzoates in pyrrolizidines 40 and 41, respective diols 42 and 43 
were obtained (Scheme 9). Diol 42 fortuitously crystalized and allowed the unequivocal 
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confirmation of its stereochemistry by single-crystal X-ray analysis.
32
 Debenzylation under 
hydrogenolysis conditions using PdCl2/H2 returned both the originally proposed structure of 
hyacinthacine C5 6 ([α]
+9.5 (c 1.00, H2O)) along with its diastereoisomer 12 ([α]
+10.3 
(c 1.00, H2O)). The NMR spectroscopic data of our synthetic 6 and 12, respectively matched 
with those of the previously synthesized 6 (∆δH = 0.01-0.04 ppm, ∆δC = 0.6-0.7 ppm) 
(lit.
23[α]
	+8.0 (c 1.00, H2O)) as well as its C6, C7 di-epimer (∆δH = 0.02-0.03 ppm, ∆δC = 
2.5-2.6 ppm, this consistent difference in chemical shifts is most likely due to differences in 
the internal reference, unfortunately this referencing information was not provided in the 
literature.
23 




	+1.5 (c 1.00, H2O)) (see Table S5 – S8 
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DMSO, 50 oC, 20 h
ii) THF, H2O, H2SO4,
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After establishing the anti-6,7-diol methodology, our attention focused on the synthesis of the 
related anti-6,7-diol compounds 7 and 10. Therefore, parent pyrrolizidines 26 and 27 were 
individually subjected to O-benzylation at C1, where the resulting products 44 (89 %) and 45 
(78 %) were hydrolyzed to give their respective C6, C7- syn-diols 46 (98 %) and 47 (85 %) 
(Scheme 10). At this point, both syn-diols were extensively characterized by NOE 
experiments to confirm their relative configurations, where it was found that 46 showed key 
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correlations between H1''‒H6, H1''‒H7, H1''‒H3, H5‒H7a, H6‒H7, H7a‒H2 and H1'‒H2 
(Figure 4). In comparison, 47 showed key positive correlations between H1''‒H3, H5‒H7a, 
H5‒H6, H5‒H7, H6‒H7, H7‒H7a, H7a‒H2 and H1'‒H2 (Figure 4). As shown in Scheme 10, 
both diols 46 and 47 underwent synthesis to their respective cyclic sulfates, 48 and 49. The 
cyclic sulfates were then subject to C6 or C7 stereoinversion using our earlier established 
ring-opening pathway with in situ formed CsOBz (Scheme 10). Ring-opening of 48 gave an 
inseparable mixture of two pyrrolizidines, 50 and 51 in 49 % yield. After clean hydrolysis of 
their benzoate groups, the resultant pyrrolizidines, 54 and 55, were separated in a 1 : 4 ratio 
leading us to believe their respective parent pyrrolizidines, 50 and 51, were originally 
synthesized in an approximately 1 : 4 ratio (Scheme 10). In contrast, the ring-opening 
reaction of the cyclic sulfate 49 gave a 1 : 2 mixture of benzoate pyrrolizidines 52 and 53 
which were readily separated by FCC in yields of 23 % and 39 %, respectively. Due to their 
ease of separation, pyrrolizidines 52 and 53 were the attention of gCOSY and extensive NOE 
analysis. It was observed that the proton sharing the stereogenic carbon with the newly added 
benzoate proved the most deshielded and characteristically appeared slightly above δH 5.0 
ppm. More specifically, the gCOSY analysis of 52 identified a strong correlation between 
H1'' (δH 1.32 ppm) and H5 (δH 3.42 – 3.30 ppm) which was subsequently found to strongly 
correlate to the most deshielded proton at δH 5.04 ppm, namely H6. After each proton was 
identified in a similar manner, NOE experiments showed key correlations between H1''‒H6, 
H1''‒H3, H6‒H3, H5‒H7a, H7‒H7a and H1'‒H2 (Figure 4). Using a similar method of 
reasoning, 53 was identified to have resulted from SN2 attack of the benzoate anion at the C7 
position the pyrrolizidine. Subsequent NOE experiments showed key correlations between 
H1''‒H3, H5‒H6, H7‒H1, H7a‒H2 and H1'‒H2 (Figure 4). Base mediated hydrolysis of the 
benzoate group in pyrrolizidines 52 and 53 provided their respective diols 54 (90 %) and 55 
(83 %) (Scheme 10). It was noted that the 
1
H NMR and 
13
C NMR spectra of these 
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pyrrolizidines were different to that of their parent pyrrolizidines 46 and 47 which clearly 
indicated successful configurational inversion at either C6 or C7.  
Scheme 10. Synthesis of pyrrolizidine diols 54 and 55 
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Figure 4. Experimental NOE NMR correlations projected onto DFT minimized molecular 
models (B3LYP/6-31G(d)) of 46, 47, 52 and 53 (Bn groups not shown) 
 
The regiochemical outcome of the ring-opening reaction of the cyclic sulfate 48 with CsOBz 
can be described by considering the two possible reactive conformations 48A and 48B of 
cyclic sulfate 48, and the preference for 1,2-diaxial-like ring opening, as shown in Scheme 
11. In this example, attack predominates at C8b of conformer 48A resulting in 51 as the 
major regioisomer. When considering conformation 48B, attack at C3a is less likely to occur 
due to unfavorable steric interactions between the nucleophile (
-
OBz) and the pseudoaxial C4 
methyl group and the pseudoaxial proton H3a. Our experimental findings suggest that cyclic 
sulfate 49 favors preference for nucleophile addition of the benzoate at C8b, perhaps owing 
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Scheme 11. Proposed reactive conformers of 48 to give the major benzoate 51 along with the 
minor benzoate 50 
 
With the two pyrrolizidines in hand, debenzylation of 54 and 55 under hydrogenolysis 
conditions (PdCl2/H2) returned hyacinthacine C-type compounds 7 ([α]
+5.2 (c 1.00, 
H2O)) and 10 ([α]





H NMR and 
13
C NMR spectroscopic data of our synthetic 7 (∆δH = 0.11-0.15 
ppm, ∆δC = 2.9-3.0 ppm, respectively) were found to be essentially identical after considering 
differences in NMR spectra referencing
47
 (see Tables S1 and S2 in the Supporting 
Information) with those of the isolate named hyacinthacine C5 (lit.
21	[α] +1.5 (c 0.22, 
H2O)) in 2007. Thus the correct structure of hyacinthacine C5 has the opposite configuration 
at the three contiguous stereogenic centers, C5, C6 and C7 to that of the originally proposed 
structure 6 (Figure 1). The authors on the isolation of this natural product had determined the 
correct relative configurations of the individual A and B-rings of hyacinthacine C5, but had 
incorrectly assigned the absolute configurations of these two rings. Confirmation of these 
assignments we made were through detailed NOESY studies (see Supporting Information) 
which unequivocally showed this to be the correct structure.  
However, when comparing the NMR spectroscopic data of our synthetic compound 10 
([α]
+6.8 (c 1.00, H2O)) and its HCl salt 10.HCl ([α]
-4.5 (c 1.00, H2O)) with those 
reported for the (+)-enantiomer (lit.
22	[α]
+0.75 (c 0.48, H2O)), prepared by Reissig and 
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 we noted significant differences (Table 1 and Table 2). In the 
1
H NMR spectrum 
of compound 10, the chemical shifts of H3, H5 and H7a appeared upfield in comparison to 
those in the Reissig and Goti’s product. Furthermore, the chemical shifts of the 
aforementioned protons in 10.HCl appeared significantly downfield when compared with 
Reissig and Goti’s sample (Table 1).  
Table 1. Comparison of literature 
1
H NMR data of (+)-5-epi-6 ((+)-10) (400 MHz, D2O)
22
 
with synthetic 10 and 10.HCl (500 MHz, D2O) 
 
Comparison of the 
13
C NMR spectroscopic data of both 10 and 10.HCl with those published 
for 5-epi-6,
22
 suggest the chemical shifts for the earlier synthesized compounds are more 
closely aligned with 10.HCl, however, there is still significant differences (especially for C2, 
C3, C5, C7a and C8) and we must conclude that they are not the same compound.  
 
Table 2. Comparison of literature 
13
C NMR data of (+)-5-epi-6 ((+)-10) (100 MHz, D2O)
22
 
with synthetic 10 and 10.HCl 
13
C NMR (125 MHz, D2O) 
Proton 







Synthetic 10.HCl  
δH (ppm) 
1 3.99 4.07-3.97 4.24 
2 3.80 3.90 3.99 
3 3.41 3.33 3.78-3.70 
5 3.64-3.56 3.41 4.06 
6 3.95 4.07-3.97 4.15 
7 4.15 4.18 4.40 
7a 3.28 3.07 3.78-3.70 
8α/β 3.64-3.56 3.67 3.81 
9 1.21 1.24 1.46 
Carbon 









1 76.7 78.0 75.6 
2 75.3 77.9 73.6 
3 63.4 62.2 65.2 
5 60.8 58.1 64.0 
6 79.1 79.7 or 78.6 79.4 
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These results prompted us to conduct extensive NOE experiments on compound 10, finding 
key correlations between H7‒Me, H1‒H7, H5‒H6, H2‒H7a, H6‒H7a and Me‒H3 (Figure 5). 
To support our findings, synthetic 10 was peracetylated to the pentaacetate 56 in near 
quantitative yield (Scheme 12). NOE studies on this compound showed significant 
correlations between H1‒H7, H2‒H7a, H5‒H6, H2‒H8, H6‒H7a and Me‒H3 (Figure 5). 
These correlations are consistent with our proposed structures for 10 and 56.  
 








7 76.8 79.7 or 78.6 76.50 
7a 74.1 72.1 76.46 
8 59.1 62.9 56.5 
9 9.5 10.7 9.2 
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Figure 5. Experimental NOE NMR correlations projected onto DFT minimized molecular 
models (B3LYP/6-31G(d)) of 10 and 56 (acetate methyl protons removed) 
 
 
The absolute configuration assigned at C3 in 26 and 27, the precursors to 7 and 10, 
respectively, was fully consistent with our NOE/ROESY NMR analyses and was that 
expected based on our previous studies,
13 
the stereochemical outcome in the cyclization 
reaction of 34 to 35 (Scheme 8), and our understanding of the mechanism of the O-
mesylation-cyclisation reaction. This involves initial O-mesylation of the less hindered 
hydroxy of the amino-diols 24 and 25 and then an SN2-type ring closure to form the desired 
pyrrolizidine products 26 and 27.
13,22,48
 However, there is also the potential for double 
inversion at the participating carbinol carbon in this process if the secondary mesylate is first 
displaced by a chloride ion to give the corresponding inverted secondary chloride. This could 
then cyclize to the corresponding pyrrolizidine with overall retention of configuration at the 
newly formed C3 stereocenter. If this has been the case, our differences between 10 and the 
literature reported (+)-5-epi-6
22
 could be accounted for. However, after an aqueous work of 
the initial mesylation reactions of 26 and 27, only the mono O-mesylated intermediate was 
observed in the 
1
H NMR spectra of the crude reaction mixtures. Furthermore, in the case of 
the mesylate reaction of 24, the mesylate intermediate could be isolated pure by FCC. Indeed, 
our 2D and 1D NOE NMR analyses of all the pyrrolizidine products were consistent with 
each of these cyclization reactions proceeding with inversion.  
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Natural (+)-hyacinthacine C5 7, along with all synthesized epimers 6, 8-12, were tested 
against a panel of enzymes (see Tables S9 and S10 in the Supporting Information) to test 
their suitability as potential glycosidase inhibitors. Key findings from our B-ring syn-diol 
series (8, 9 and 11) were that compounds 8 and 9 showed weak to moderate inhibition of the 
α-glucosidase of rat intestinal isomaltase (IC50 values of 20 µM and 42 µM, respectively) and 
moderate inhibition against the α-glucosidase of rat intestinal sucrase (IC50 values of 13 µM 
and 9.9 µM, respectively). Compound 8 proved to be a weak inhibitor against yeast α-
glucosidase (IC50 values of 83 µM) and rat intestinal maltase (IC50 values of 61 µM) but 
showed moderate activity against amylglucosidases from Aspergillus niger and Rhizopus sp 
(IC50 values of 25 µM and 16 µM, respectively). Compound 11 proved relatively inactive 
amongst the entire panel of enzymes. In comparison, the B-ring anti-diol series (6, 7, 10 and 
12) found compound 10 to have moderate inhibition against α-glucosidases of rat intestinal 
maltase and human lysosome (IC50 values of 21 µM and 15 µM, respectively) and weak 
inhibition against the amylglucosidase of Aspergillus niger (IC50 values of 41 µM). Besides 
10, only compound 6 was noted to display a weak inhibition against the α-L-rhamnosidase of 
Penicillium decumbens (IC50 values of 74 µM). From our results of this inhibition assay, we 
noted correlation between the orientation of the C5 methyl group and the IC50 against each 
glycosidase tested. More specifically, if the hyacinthacine C-type alkaloid contains a (5S)-
methyl the IC50 values increase with consequently a reduction in the selectivity and potency 
of the compound as a glycosidase inhibitor. Comparatively, for a decrease in the IC50, the 
hyacinthacine C-type compounds containing an (5R)-methyl proved more suitable candidates 
for potential as glycosidase inhibitors.  
When compared against casuarine (see Supporting Information), (+)-5-nor-methyl-
hyacinthacine C5, the glycosidase inhibition against common α-glucosidases were less potent 
for all synthetic hyacinthacine C5 analogues 6-12. This suggests that regardless of 
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stereochemical orientation, a methyl substituent at C5 obstructs the interaction of the 
pentahydroxypyrrolizidine molecule with the α-glycosidase active site. 
CONCLUSIONS 
In conclusion, we have successfully developed and employed the total synthesis of the seven 
hyacinthacine C5 type compounds which has resulted in the revision of the structure of 
hyacinthacine C5 from 6 to that of structure 7. Our syntheses and spectral analysis of 
compounds 6, 11 and 12 also confirm the proposed structures and absolute configurations of 






 respectively. Structures and 
absolute configurations for compounds 7, 8, 9 and 10 have been established through 
extensive spectroscopic studies and crystal structures of several key precursors. Our synthetic 
10 does not spectroscopically match with the same structure previously reported.
22
 Our 
enzyme inhibition studies suggest that relative to casuarine, the C5 methyl substituted 
derivatives prepared here were generally less potent glycosidase inhibitors. 
EXPERIMENTAL SECTION 
General Information. 
Flash column chromatography (FCC) using silica gel 60 230-400 Mesh was used for 
purifications. LRESIMS were determined on a single quadrupole (MeOH as solvent) mass 
spectrometer. HRESIMS were determined on a quadrupole time-of-flight mass spectrometer. 
IR spectra data were determined on neat samples. The optical rotation was measured using a 
2 mL cell at room temperature. An average of forty measurements was used to calculate the 
specific rotation. 
1
H (500 MHz) and
 13
C NMR (125 MHz) spectra were recorded in 
deuterochloroform (CDCl3), deuterium oxide (D2O) or deuterated methanol (CD3OD) 
solutions. All signals which were recorded in CDCl3 were relative to the tetramethylsilane 
(TMS) signal for 
1
H NMR and the CDCl3 signal for 
13
C NMR, referenced at 0.00 ppm and 
77.16 ppm, respectively. All signals which were recorded in CD3OD were relative to the 
CD2HOD signal for 
1




C NMR, referenced at 3.31 ppm and 
49.00 ppm, respectively. All signals which were recorded in D2O were relative to the D2O 
signal for 
1
H NMR, referenced at 4.49 ppm. For 
13
C NMR the referencing of peaks is relative 
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to internal MeOH (δ 49.50 ppm). NMR assignments were based upon gCOSY, APT, 
gHSQC, and NOESY or ROESY experiments. In some cases,
 13
C NMR signals that were 
absent in the standard 
13
C NMR spectrum were identified using gHSQC experiments. 
Pyrrolizidine compounds are named using systematic nomenclature. The NMR assignments 
of those compounds are based on the numbering system of the hyacinthacine alkaloids and 
not the systematic name. The three-dimensional structures generated were prepared with 
ChemDraw 16.0 and Avogadro: an open-source molecular builder and visualization tool. 
Version 1.2.0.
49
 The Density Functional Theory (DFT) used to minimize the three-
dimensional structures was calculated with B3LYP/6-31G(d)
50–52





Synthesis of (5R) pyrrolizidines 
 
General Method for the Petasis (Borono-Mannich) reaction 
 
(2S,3S,4R,5R,E)-1,3-Bis(benzyloxy)-5-(((R)-but-3-en-2-yl)amino)-7-phenylhept-6-
ene-2,4-diol (16). Triethylamine (434 µL, 2.83 mmol) was added to a solution of (R)-α-
methylallyl amine·HCl (0.220 g, 3.12 mmol) in EtOH (50 mL) and the solution was stirred at 
rt for 20 min. (+)-3,4-Di-O-benzyl-α,β-L-xylofuranose
29–31
 (0.930 g, 2.83 mmol) was then 
added to the reaction mixture, followed by the addition of (E)-2-phenylvinylboronic acid 
(0.460 g, 3.12 mmol). TLC analysis confirmed complete consumption of the starting material 
after stirring at rt for 3 d, whereby the mixture was then concentrated in vacuo, affording a 
brown viscous oil. The crude product was dissolved in EtOAc (50 mL) and washed with 0.5 
M NaOH (2 x 40 mL) solution. The organic fraction was then dried (MgSO4), filtered, 
concentrated in vacuo and purified by FCC (3:97 MeOH/CH2Cl2) affording the desired 
product 16 as a brown oil (0.900 g, 65%). To prepare the crystalline hydrochloride salt of 16, 
a portion of 16 (0.100 g) was dissolved in CH2Cl2 (5 mL) and washed with 1N HCl (3 x 10 
mL). The CH2Cl2 solution was concentrated in vacuo to give 16.HCl as white needle-like 
crystals. 16 Rf 0.20 (3:97 MeOH/CH2Cl2). [α]
-40.9 (c 1.00, CHCl3). IR υmax (cm
-1
): 3389, 
3298, 3061, 3029, 2921, 2863, 1497, 1451, 1366, 1073, 975, 916, 740, 641. 
1
H NMR (500 
MHz, CDCl3) δ 7.37 – 7.20 (15H, m, ArH), 6.48 (1H, d, J = 16.0 Hz, H7), 6.10 (1H, dd, J = 
16.0, 8.7 Hz, H6), 5.72 (1H, ddd, J = 17.3, 10.2, 7.2 Hz, H2՛), 5.09 (1H, d, J = 10.2 Hz, 
H3՛cis), 4.98 (1H, d, J = 16.8 Hz, H3՛trans), 4.64 (2H, s, OCH2Ph), 4.51 – 4.42 (2H, m, 
OCH2Ph), 4.05 (1H, dd, J = 8.3, 5.5 Hz, H2), 3.97 (1H, t, J = 4.6 Hz, H4), 3.69 – 3.49 (4H, 
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m, H3, H1, H5), 3.30 (1H, dq, J = 12.6, 6.2, Hz, H1՛), 1.10 (3H, d, J = 6.4 Hz, H1՛՛). 13C 
NMR (125 MHz, CDCl3) δ 142.0 (C2՛), 138.3 (ArC), 138.2 (ArC), 136.8 (ArC), 133.6 (C7), 
128.8 (ArCH), 128.3 (ArCH), 128.0 (C6, ArCH), 128.0 (ArCH), 127.0 (ArCH), 126.7 
(ArCH), 114.9 (C3՛), 80.1 (C3), 74.5 (OCH2Ph), 73.6 (OCH2Ph), 72.4 (C4), 71.5 (C1), 70.3 
(C2), 60.6 (C5), 53.0 (C1՛), 20.3 (C1՛՛). LRESIMS m/z 488 (100%) [M+H]+. HRMS (ESI-
TOF) m/z: [M+H]
+ 
Calcd for C31H38NO4, 488.2801; found 488.2813. 16.HCl Rf 0.15 (5:97 




H NMR (500 MHz, CDCl3) δ 7.47 – 7.07 (15H, m, 
ArH), 6.69 (1H, d, J = 16.0 Hz, H7), 6.43 (1H, dd, J = 16.0, 9.9 Hz, H6), 6.03 (1H, ddd, J = 
17.5, 10.4, 7.4 Hz, H2՛), 5.32 – 5.20 (2H, m, H3՛), 4.80 (1H, d, J = 10.9 Hz, OCH2Ph), 4.68 – 
4.57 (1H, m, H5), 4.55 – 4.29 (3H, m, OCH2Ph, H4), 4.20 (1H, dd, J = 9.9, 3.4 Hz), 4.10 
(2H, dd, J = 6.3, 4.3 Hz), 3.81 – 3.68 (2H, m, H3, H1՛), 3.63 (1H, dd, J = 6.8, 1.9 Hz, H2), 
3.53 (1H, dd, J = 9.4, 6.5 Hz, H1), 3.42 (1H, dd, J = 9.4, 6.0 Hz, H1), 1.46 (3H, d, J = 6.8 Hz, 
H1՛՛). 13C NMR (125 MHz, CDCl3) δ 138.7 (C2՛), 137.9 (ArC), 137.6 (ArC), 135.2 (ArC), 
134.7 (C7), 128.9 (ArCH), 128.8 (ArCH), 128.4 (ArCH), 127.9 (ArCH), 127.69 (ArCH), 
127.68 (ArCH), 127.19 (ArCH), 120.18 (C3՛), 78.8 (C3), 74.8 (OCH2Ph), 73.2 (OCH2Ph), 
70.9 (C4), 69.9 (C1), 68.6 (C2), 62.1(C5), 54.9 (C1՛), 16.7 (C1՛՛). 
 
(4R,5R)-5-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-3-((R)-but-3-en-2-yl)-4-
((E)-styryl)oxazolidin-2-one (17) and (4R,5R,6S,7S)-6-(Benzyloxy)-7-
((benzyloxy)methyl)-3-((R)-but-3-en-2-yl)-5-hydroxy-4-((E)-styryl)-1,3-oxazepan-2-one 
(18). Procedure A: Compound 16 (540 mg, 1.11 mmol) was dissolved in anhydrous CH2Cl2 
(40 mL) and cooled to 0 
o
C under an atmosphere of nitrogen. Triethylamine (310 µL, 2.22 
mmol) was added and after 15 min triphosgene (164 mg, 0.555 mmol) was added portionwise 
and the solution was allowed to warm to rt. After stirring for 1 h, TLC analysis confirmed full 
consumption of the starting material. The reaction was diluted with H2O (15 mL) and 
extracted with CH2Cl2 (3 x 15 mL). The combined extracts were dried (MgSO4), filtered and 
concentrated in vacuo to afford a brown oil which whereby purification by FCC (gradient of 
1:5 EtOAc/hexane to 1:1 EtOAc/hexane) produced an inseparable mixture of isomers (37 %, 
1:2) consisting of the oxazolidinone and the oxazepinone respectively. Pure samples of 17 
(12 mg) and 18 (20 mg) could be obtained for analytical purposes.  
Procedure B: To solution of 19 (500 mg, 0.851 mmol) in dry THF (15 mL) at 0 
o
C was added 
NaH (85.0 mg, 2.13 mmol, 60% in mineral oil). The mixture was then heated at 65 
o
C for 45 
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min, or until full consumption of 19 by TLC analysis. The reaction mixture was then cooled 
to 0 
o
C, and quenched by the slow addition of water (10 mL). The solution was then extracted 
with EtOAc (3 x 20 mL). The combined extracts were dried (MgSO4), filtered and 
concentrated in vacuo. Purification by FCC (1:1 EtOAc/hexane) returned the oxozolidinone 
17 as a pale-yellow oil (372 mg, 85 %). 17 Rf 0.65 (1:1 EtOAc/hexane). [α]
-23.5 (c 1.00, 
CHCl3). IR υmax (cm
-1): 3428, 3025, 2931, 2866, 1744, 1452, 1410, 1212, 1095, 1062, 1025, 
921, 736, 624. 
1
H NMR (500 MHz, CDCl3) δ 7.39 – 7.19 (13H, m, ArH), 7.18 – 7.00 (2H, m, 
ArH), 6.56 (1H, d, J = 15.8 Hz, H2՛՛՛), 6.12 (1H, dd, J = 15.8, 10.9 Hz, H1՛՛՛), 5.99 – 5.89 
(1H, m, H2՛), 5.25 – 5.09 (2H, m, H3՛), 4.85 (1H, t, J = 7.1 Hz, H5), 4.80 (1H, d, J = 11.1 Hz, 
OCH2Ph), 4.56 (1H, d, J = 11.2 Hz, OCH2Ph), 4.47- 4.39 (2H, m, H4, H1՛), 4.32 (2H, s, 
OCH2Ph), 3.96 (1H, s, H2՛՛՛՛), 3.79 (1H, dd, J = 7.0, 2.3 Hz, H1՛՛՛՛), 3.53 – 3.39 (2H, m, 
H3՛՛՛՛), 2.37 (1H, s, OH), 1.30 (3H, d, J = 6.5 Hz, H1՛՛). 
13
C NMR (125 MHz, CDCl3) δ 
156.9 (C2), 137.93 (ArC), 137.89 (ArC), 136.9 (C2՛), 135.6 (ArC), 135.4 (C2՛՛՛), 129.2 (2 x 
ArCH), 128.9 (ArCH), 128.7 (4 x ArCH), 128.5 (2 x ArCH), 127.9 (ArCH ), 127.2 (ArCH), 
127.3 (2 x ArCH), 126.7 (2 x ArCH), 124.7 (C1՛՛՛), 117.1 (C3՛), 77.8 (C5), 76.5 (C1՛՛՛՛), 74.2 
(OCH2Ph), 73.1 (OCH2Ph), 70.6 (C3՛՛՛՛), 68.9 (C2՛՛՛՛), 60.0 (C4), 51.7 (C1՛), 18.4 (C1՛՛). 
LRESIMS m/z 536 (100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+
 Calcd for 
C32H35NO5Na 536.2413; Found 536.2433. 18 Rf 0.65 (1:1 EtOAc/hexane). [α]
+86.0 (c 
1.00, CHCl3). IR υmax (cm
-1): 3388, 3029, 2934, 2870, 1664, 1451, 1249, 1103, 1052, 1001, 
794, 624. 
1
H NMR (500 MHz, CDCl3) δ 7.35 - 7.16 (13H, m, ArH), 7.12 - 7.06 (2H, m, 
ArH), 6.69 (1H, dd, J = 15.9, 9.0 Hz, H1‴), 6.43 (1H, d, J = 15.9 Hz, H2‴), 6.06 (1H, ddd, J = 
17.4, 10.5, 5.1 Hz, H2′), 5.34 (1H, d, J = 10.0 Hz, H3′cis), 5.31 (1 H, d, J = 16.2 Hz, H3′trans), 
4.79 (1H, td, J = 6.8, 1.8 Hz, H1′), 4.62 (1H, d, J = 11.8 Hz, OCH2Ph), 4.53 - 4.50 (3H, m, 
H7 and 2 x OCH2Ph), 4.40 (1 H, d, J = 11.2 Hz, OCH2Ph), 4.07 - 4.04 (1H, m, H5), 4.01 (1 
H, dd, J = 9.0, 4.3 Hz, H4), 3.83 (1H, dd, J = 9.3, 6.0 Hz, H1‴′), 3.78 (1H, d, J = 9.3 Hz, 
H1‴′), 3.75 - 3.73 (1H, m, H6), 1.84 (1H, d, J = 5.8 Hz, OH), 1.28 (3H, d, J = 6.8 Hz, H1″). 
13
C NMR (125 MHz, CDCl3) δ 158.4 (C2), 139.2 (C2′), 138.0 (ArC), 137.6 (ArC), 136.5 
(ArC), 131.6 (C2‴), 128.7 (ArCH), 128.6 (2 x ArCH), 128.3 (ArCH), 128.1 (ArCH), 128.0 
(ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.3 (C1‴), 126.8 (ArCH), 118.1 (C3′), 78.2 (C6), 
74.8 (C7), 73.6 (OCH2Ph), 72.9 (OCH2Ph), 69.0 (C5), 68.4 (C1‴′), 61.6 (C4), 55.6 (C1′), 16.1 
(C1″). LRESIMS m/z 536 (100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+
 Calcd for 
C32H35NO5Na 536.2413; Found 536.2415. 
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3-yl)((R)-but-3-en-2-yl)carbamate (19). To a solution of 16 (1.10 g, 2.25 mmol) in dry 1,2-
dichloroethane (10 mL) was added dry N,N-diisopropylethylamine (784 µL, 4.50 mmol) and 
di-tert-butyl-dicarbonate (0.980 g, 4.50 mmol). The reaction mixture was stirred at 70 
o
C for 
48 h. CH2Cl2 (15 mL) was added and the solution was washed with 1 M HCl (2 x 20 mL), 
and brine. The organic fraction was then dried (MgSO4), filtered and concentrated in vacuo. 
Purification by FCC (1:4 EtOAc/hexane, then to 5:95 MeOH/CH2Cl2) gave 19 (0.820 g, 
62%) and recovered starting material 16 (0.250 g, 23%) as pale-yellow and brown oils, 
respectively. Rf 0.30 (3:7 EtOAc/hexane). [α]
+46.5 (c 1.00, CHCl3). IR υmax (cm
-1
): 3383, 
3029, 2976, 2869, 1680, 1253, 1094. 
1
H NMR (500 MHz, CDCl3) δ 7.40 – 7.19 (15H, m, 
ArH), 6.59 (1H, dd, J = 16.1, 7.0 Hz, H6), 6.49 (1H, d, J = 16.1 Hz, H7), 5.97 (1H, ddd, J = 
17.0, 10.7, 4.9 Hz, H2՛), 5.06 (1H, t, J = 13.8 Hz, H3՛), 4.74 (1H, d, J = 11.2 Hz, OCH2Ph), 
4.67 (1H, d, J = 11.2 Hz, OCH2Ph), 4.51 (1H, d, J = 11.8 Hz, OCH2Ph), 4.46 (1H, d, J = 11.8 
Hz, OCH2Ph), 4.40 – 4.27 (2H, m, H1՛, H5), 4.09 (2H, s, H4, H2), 3.65 (1H, bs, H3), 3.56 
(2H, app. q, J = 9.5, 8.2 Hz, H1A,B), 1.47 (9H, s, (CH3)3C), 1.26 (2H, d, J = 6.7 Hz, H1՛՛). 
13
C 
NMR (125 MHz, CDCl3) δ 139.8 (C2՛), 138.2 (CO), 138.1 (ArC), 137.0 (ArC), 133.25 (C7), 
128.5 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 
127.6 (ArCH), 126.6 (C6), 115.4 (C3՛), 80.8 (CH3)3C), 78.5 (C3), 74.9 (C4 or C2), 74.5 
(OCH2Ph), 73.4 (OCH2Ph), 71.4 (C1), 70.8 (C4 or C2), 59.6 (C1՛), 54.5 (C5), 28.6 (CH3)3C), 
18.2 (C1՛՛). LRESIMS m/z 588 (100%) [M+H]+. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C36H46NO6 588.3325; Found 588.3311.  
 
General method for Ring-closing Metathesis 
 
(1R,5R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-methyl-5,7a-
dihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (20). A solution of 17 (162 mg, 0.316 mmol) in 
anhydrous CH2Cl2 (10 mL) was treated with Grubbs’ II ruthenium catalyst (14 mg, 0.016 
mmol). The mixture was heated at reflux for 4 h under a nitrogen atmosphere, by which time, 
TLC analysis confirmed full consumption of the starting material. The solution was then 
concentrated in vacuo to afford a black oil. Purification by FCC (gradient of 1:1 
EtOAc/hexane to 4:1 EtOAc/hexane) afforded the title compound 20 as a pale-brown gum 
(110 mg, 85%). Rf 0.19 (1:1 EtOAc/hexane). [α]
-24.6 (c 1.00, CHCl3). IR υmax (cm
-1
): 
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3441, 3031, 2929, 2870, 1741, 1370, 1267, 1066, 739, 698. 
1
H NMR (500 MHz, CDCl3) δ 
7.40 – 7.19 (10H, m, ArH), 5.81 (1H, d, J = 6.6 Hz, H7), 5.79 (1H, d, J = 6.6 Hz, H6), 5.04 
(1H, s, H1), 4.86 (1H, dd, J = 8.5, 4.8, H7a), 4.68 (1H, d, J = 11.2, OCH2Ph), 4.54 (1H, d, J = 
11.2 Hz, OCH2Ph), 4.50 (1H, d, J = 11.8 Hz, OCH2Ph), 4.45 (1H, d, J = 11.8 Hz, OCH2Ph), 
4.26 (1H, app. t, J = 6.3 Hz, H5), 3.95 (1H, dd, J = 6.1, 3.7 Hz, H2՛), 3.65 – 3.56 (3H, m, 
H3՛, H1՛), 2.51 (1H, d, J = 5.7, OH), 1.39 (3H, d, J = 6.8, H1՛՛). 13C NMR (125 MHz, CDCl3) 
δ 156.5 (C3), 137.9 (ArC), 137.5 (ArC), 137.4 (C6), 128.5 (2 x ArCH), 128.4 (2 x ArCH), 
128.2 (2 x ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (2 x ArCH), 123.8 (C7), 77.0 (C1՛), 
75.9 (C7a), 73.9 (OCH2Ph), 73.4 (OCH2Ph), 71.1 (C3՛), 69.3 (C2՛), 68.6 (C1), 60.0 (C5), 
16.1 (C1՛՛). LRESIMS m/z 432 (100 %) [M+Na]+. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd 
for C24H27NO5Na 432.1787; Found 432.1793.  
 
General method for cis-dihydroxylation 
 
(1R,5R,6S,7R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-6,7-
dihydroxy-5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (21a) and 
(1R,5R,6R,7S,7aR)-1-((1R,2S)-1,3-bis(benzyloxy)-2-hydroxypropyl)-6,7-dihydroxy-5-
methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (21b). Compound 20 (177 mg, 0.432 
mmol) was dissolved in acetone/water (3:1, 12 mL,) and the solution was cooled to 0 
o
C. N-
methylmorpholine-N-oxide (103 mg, 0.879 mmol) and potassium osmate dihydrate (9.6 mg, 
0.026 mmol) were then added and the solution was stirred vigorously at 35 
o
C for 48 h. The 
reaction was concentrated in vacuo, affording a black viscous oil which was diluted with H2O 
(20 mL) and extracted with EtOAc (3 x 15 mL). The combined extracts were dried (MgSO4), 
filtered and concentrated in vacuo to afford a black oil which was subsequently purified by 
FCC (gradient of 5:95 MeOH/CH2Cl2 to 1:9 MeOH/CH2Cl2). This gave pure samples of the 
title compounds 21a (10 mg, 5%), and 21b (7 mg, 4%), as colorless oils, and a 3.5:1 mixture 
of 21a and 21b (132 mg, 69%). 21a Rf 0.10 (5:95 MeOH/CH2Cl2). [α]
-4.1 (c 1.00, 
CHCl3). IR υmax (cm
-1
): 3394, 2940, 1454, 1375, 1259, 1212, 1154, 1071, 1028, 866. 
1
H 
NMR (500 MHz, CDCl3) δ 7.41 – 7.21 (10H, m, ArH), 4.93 – 4.81 (2H, m, H1, OCH2Ph), 
4.62 (1H, d, J = 11.3 Hz, OCH2Ph), 4.43 (1H, d, J = 11.5 Hz, OCH2Ph), 4.35 (1H, d, J = 11.5 
Hz, OCH2Ph), 4.08 (1H, t, J = 8.4, H7a) 4.05– 3.98 (2H, m, H6, H2՛), 3.89 (1H, dd, J = 8.0, 
1.8 Hz, H1՛), 3.78 (1H, d, J = 4.4 Hz, H7), 3.60 – 3.51 (2H, m, H5, H3՛), 3.38 (1H, dd, J = 
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9.0, 7.3 Hz, H3՛), 2.86 – 2.70 (2H, m, 2 x OH), 1.46 (3H, d, J = 8.9 Hz, H1՛՛). 13C NMR (125 
MHz, CDCl3) δ 156.7 (C3), 137.5 (ArC), 137.2 (ArC), 128.9 (ArCH), 128.8 (ArCH), 128.7 
(ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 79.6 (C7), 75.6 (C1՛), 74.6 (C1), 74.5 
(OCH2Ph), 73.8 (OCH2Ph), 70.7 (C3՛), 68.4 (C6, C2՛), 65.1 (C7a), 59.7 (C5), 15.4 (C1՛՛). 
LRESIMS m/z 466 (100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+
 Calcd for 
C24H29NO7Na 466.1842; Found 466.1858. 21b Rf 0.08 (5:95 MeOH/CH2Cl2). [α]
+24.9 (c 
1.00, CHCl3). IR υmax (cm
-1
): 3297, 2940, 1480, 1315, 1270, 1031, 853. 
1
H NMR (500 MHz, 
CDCl3) δ 7.42 – 7.29 (8H, m, ArH), 7.29 – 7.15 (2H, m, ArH), 4.99 – 4.86 (2H, m, H1, 
OCH2Ph), 4.56 (1H, d, J = 11.2 Hz, OCH2Ph), 4.42 (1H, d, J = 11.4 Hz, OCH2Ph), 4.38 (1H, 
d, J = 9.0 Hz, H1՛), 4.33 (1H, d, J = 11.4 Hz, OCH2Ph), 4.28 (1H, ddd, J = 10.7, 9.6, 3.8 Hz, 
H6), 4.04 (1H, d, J = 2.1 Hz, H7), 3.92 – 3.84 (2H, m, H7a, OH), 3.82 – 3.70 (2H, m, H5, 
H2՛), 3.49 (1H, dd, J = 8.6, 5.0 Hz, H3՛), 3.23 (1H, t, J = 8.5 Hz, H3՛), 2.75 (1H, d, J = 10.5 
Hz, OH), 2.72 (1H, d, J = 9.2 Hz, OH), 1.48 (3H, d, J = 7.0 Hz, H1՛՛). 13C NMR (125 MHz, 
CDCl3) δ 156.7 (C3), 137.6 (ArC), 136.8 (ArC), 129.0 (ArCH), 128.9 (ArCH), 128.7 
(ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 77.1 (C1), 75.2 (C1՛), 74.9 (C6), 74.9 
(OCH2Ph), 73.9 (OCH2Ph), 70.8 (C7), 70.8 (C3՛), 68.7 (C2՛), 62.5 (C7a), 54.5 (C5), 11.9 
(C1՛՛). LRESIMS m/z 466 (100%) [M+Na]+. 
 
General method for acetonide protection of cis-diols 
 
(3aR,3bR,4R,8R,8aS)-4-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-2,2,8-
trimethyltetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one (22) and 
(3aS,3bR,4R,8R,8aR)-4-((1R,2S)-1,3-bis(benzyloxy)-2-hydroxypropyl)-2,2,8-
trimethyltetrahydro-4H,6H-[1,3]dioxolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one (23). To 
anhydrous acetone (2 mL) was added in order, concentrated H2SO4 (1.6 µL, 0.032 mmol), 
anhydrous CuSO4 (36 mg, 0.23 mmol) and a solution of compound 21a (50 mg, 0.11 mmol) 
in acetone (1 mL). After vigorous stirring at rt for 1 h under a nitrogen atmosphere, TLC 
analysis confirmed full consumption of the starting diol. The reaction mixture was then 
vacuum filtrated through a celite pad, and the pad was washed with additional acetone (3 x 2 
mL). The filtrate was basified with 30% NH3 solution (10.5 µL) and the (NH4)2SO4 
precipitate was separated from the solution by gravity filtration. The filtrate was then 
concentrated in vacuo and purified by FCC (2:98 MeOH/diethyl ether) to afford compound 
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22 as a clear oil (52 mg, 99%). Using this exact same method, compound 21b (40 mg, 0.088 
mmol), was also treated under similar conditions, using acetone (2 mL), H2SO4 (1.3 µL, 
0.026 mmol), anhydrous CuSO4 (29 mg, 0.18 mmol), additional acetone (3 x 2 mL) and 
concentrated NH3 (8.4 µL). Purification by FCC (2:98 MeOH/diethyl ether), afforded 
compound 23 as a clear oil (42 mg, 99%). This method was also used on a mixture of the two 
isomers 21a and 21b. More specifically, to dry acetone (5 mL) was added in order, 
concentrated H2SO4 (4 µL, 0.076 mmol), anhydrous CuSO4 (95 mg, 0.596 mmol) and a 
solution of 3.5:1 respective mixture of 21a and 21b (132 mg, 0.298 mmol) in acetone (2 mL). 
Using the same method as above, the title compounds 22 (102 mg, 71%) and 23 were 
separated (34 mg, 24%) as colorless oils after purification by FCC (2:98 MeOH/diethyl 
ether). 22 Rf 0.60 (2:98 MeOH/diethyl ether). [α]
-43.8 (c 1.00, CHCl3). IR υmax (cm
-1
): 




H NMR (500 MHz, CDCl3) δ 7.42 – 7.19 
(10H, m, ArH), 4.90 (1H, dd, J = 8.4, 6.1 Hz, H4), 4.73 (2H, q, J = 11.1 Hz, OCH2Ph), 4.59 
(1H, app. t, J = 8.7 Hz, H3a), 4.50 (2H, q, J = 11.8 Hz, OCH2Ph), 4.19 – 4.06 (3H, m, H3b, 
H8a, H2՛), 3.89 (1H, dd, J = 5.9, 2.9 Hz, H1՛), 3.60 (2H, qd, J = 9.6, 6.2 Hz, H3՛), 3.52 (1H, 
qd, J = 7.0, 4.4 Hz, H8), 2.52 (1H, d, J = 7.1 Hz, OH), 1.54 – 1.46 (6H, m, C2-CH3, H1՛՛), 
1.26 (3H, s, C2-CH3). 
13
C NMR (125 MHz, CDCl3) δ 156.2 (C6), 138.1 (ArC), 137.7 (ArC), 
128.7 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 
114.8 (C2), 88.3 (C8a), 77.8 (C3a), 77.5 (C1՛), 75.2 (C4), 74.0 (OCH2Ph), 73.5 (OCH2Ph), 
71.0 (C3՛), 69.2 (C2՛), 67.5 (C3b), 59.4 (C8), 27.6 (C2-CH3), 25.5 (C2-CH3), 15.0 (C1՛՛). 
LRESIMS m/z 506 (100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+
 Calcd for 
C27H33NO7Na 506.2155; Found 506.2180. 23 Rf 0.17 (2:98 MeOH/diethyl ether). [α]
+52.7 
(c 1.00, CHCl3). IR υmax (cm
-1
): 3239, 2916, 1454, 1380, 1246, 1208, 753. 
1
H NMR (500 
MHz, CDCl3) δ 7.42 – 7.21 (10H, m, ArH), 4.98 (1H, t, J = 8.0 Hz, H4), 4.92 (1H, d, J = 11.4 
Hz, OCH2Ph), 4.66 (1H, dd, J = 5.5, 3.7 Hz, H3a ), 4.60 – 4.47 (3H, m, H8a, OCH2Ph), 4.41 
(2H, m, OCH2Ph, H1՛), 3.88 (1H, d, J = 5.8 Hz, H2՛), 3.68 (1H, dd, J = 7.1, 3.5 Hz, H3b), 
3.57 (1H, dd, J = 9.4, 7.0 Hz, H3՛), 3.41 (1H, dd, J = 9.4, 5.6 Hz, H3՛), 3.33 (1H, dt, J = 11.1, 
5.6 Hz, H8), 2.43 (1H, d, J = 7.4 Hz, OH), 1.69 (3H, d, J = 7.0 Hz, H1՛՛), 1.48 (3H, s, C2-
CH3), 1.21 (3H, s, C2-CH3). 
13
C NMR (125 MHz, CDCl3) δ 154.5 (C6), 138.2 (ArC), 137.3 
(ArC), 128.9 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.8 
(ArCH), 95.0 (C2), 83.3 (C8a), 80.5 (C3a), 78.2 (C4), 75.7 (C1՛), 74.2 (OCH2Ph), 73.6 
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(OCH2Ph), 71.6 (C3՛), 70.6 (C2՛), 64.6 (C3b), 58.7 (C8), 26.1 (C2-CH3), 24.2 (C2-CH3), 10.3 
(C1՛՛). LRESIMS m/z 506 (100%) [M+Na]+. 
 
General method for oxazolidinone hydrolysis 
 
(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((3aS,4S,6R,6aR)-2,2,6-trimethyltetrahydro-4H-
[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (24). A solution of NaOH (46 mg, 1.15 
mmol) in H2O (3 drops) was added to a solution of oxazolidinone 22 (185 mg, 0.383 mmol) 
in EtOH (3 mL) in a microwave reaction tube. The tube was capped and the solution was 
stirred and irradiated in a CEM microwave reactor for 1 h (the temperature control was set at 
110 
o
C, and the maximum applied power at 200 W). After cooling to rt, the reaction mixture 
was concentrated in vacuo, diluted with a solution of saturated NaCl (5 mL) and extracted 
with EtOAc (3 x 10 mL). The combined extracts were concentrated in vacuo to give a brown 
oil. Purification by FCC (5:95 MeOH/CH2Cl2) gave the desired compound 24 as a pale-
yellow oil (151 mg, 86%). Rf 0.27 (5:95 MeOH/CH2Cl2). [α]
-65.4 (c 1.00, CHCl3). IR 
υmax (cm
-1
): 3344, 3063, 2984, 1453, 1208, 1064, 607. 
1
H NMR (500 MHz, CDCl3) δ 7.41 – 
7.24 (10H, m, ArH), 4.70 (2H, app. q, J = 11.3 Hz, OCH2Ph), 4.61 (1H, dd, J = 7.0, 4.7 Hz, 
H3a), 4.52 (2H, app. q, J = 11.5 Hz, OCH2Ph), 4.06 (1H, dd, J = 8.8, 5.0 Hz, H3՛), 4.01 (1H, 
dd, J = 7.0, 5.2 Hz, H6a), 3.74 (1H, dd, J = 7.0, 5.5 Hz, H1՛), 3.70 – 3.60 (3H, m, H4՛, H2՛), 
3.08 (1H, dd, J = 7.1, 4.7 Hz, H4), 3.05 – 2.98 (1H, m, H6), 2.76 (2H, bs, OH), 1.48 (3H, s, 
C2-CH3), 1.28 (3H, s, C2-CH3), 1.04 (3H, d, J = 6.6 Hz, H1՛՛). 
13
C NMR (125 MHz, CDCl3) 
δ 137.9 (ArC), 137.9 (ArC), 128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.1 (ArCH), 
128.0 (ArCH), 127.9 (2 x ArCH), 114.0 (C2), 86.7 (C6a), 83.0 (C3a), 80.1 (C2՛), 74.3 
(OCH2Ph), 73.4 (OCH2Ph), 72.3 (C1՛), 70.9 (C4՛), 70.1 (C3՛), 66.5 (C4), 59.5 (C6), 27.4 





 Calcd for C26H36NO6 458.2543; Found 458.2554. 
 
(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((3aR,4S,6R,6aS)-2,2,6-trimethyltetrahydro-4H-
[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (25). Compound 25 was synthesized from 
the oxazolidinone 23 (205 mg, 0.414 mmol) using the general method for oxazolidinone 
hydrolysis. The crude product was purified by FCC (5:95 MeOH/CH2Cl2) to give the desired 
product as a pale-yellow oil (165 mg, 87%). Rf 0.22 (5:95 MeOH/CH2Cl2). [α]
-24.9 (c 
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1.00, CHCl3). IR υmax (cm
-1
): 3423, 3065, 2989, 1453, 1230, 1067. 
1
H NMR (500 MHz, 
CDCl3) δ 7.41 – 7.20 (10H, m, ArH), 4.75 – 4.70 (2H, m, H3a, OCH2Ph), 4.63 (1H, d, J = 
11.4 Hz, OCH2Ph), 4.52 (2H, s, OCH2Ph), 4.42 (1H, t, J = 4.8 Hz, H6a), 4.06 – 3.98 (2H, m, 
H1՛, H3՛), 3.73 (1H, dd, J = 9.9, 4.2 Hz, H4՛), 3.67 (1H, dd, J = 6.1, 3.9 Hz, H2՛), 3.61 (1H, 
dd, J = 9.8, 4.6 Hz, H4՛), 2.77 – 2.65 (2H, m, H6, H4), 1.28 (3H, s, C2-CH3), 1.25 (3H, s, C2-
CH3), 1.15 (d, J = 6.6 Hz, H1՛՛). 
13
C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 138.2 (ArC), 
128.7 (ArCH), 128.7 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 
110.8 (C2), 82.7 (C6a), 82.6 (C3a), 82.6 (C2՛), 74.1 (OCH2Ph), 73.8 (OCH2Ph), 71.0 (C4՛), 
70.8 (C3՛), 70.2 (C1՛), 64.5 (C6), 58.1 (C4), 25.7 (C2-CH3), 24.1 (C2-CH3), 13.2 (C1՛՛). 
LRESIMS m/z 458 (100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+
 Calcd for C26H36NO6 




methanesulfonate (24a) and (3aR,4R,6R,7R,8R,8aS,8bS)-7-(benzyloxy)-6-
((benzyloxy)methyl)-2,2,4-trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol 
(26). Procedure A: Triethylamine (16 µL, 0.116 mmol) was slowly added to a solution of 24 
(53 mg, 0.116 mmol) in anhydrous CH2Cl2 (8 mL) at 0 
o
C under a N2 atmosphere. Whilst 
stirring, a 0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (0.893 mL, 
0.116 mmol) was slowly added to the reaction mixture. After stirring at 0 
o
C for 1.5 h, TLC 
analysis confirmed full consumption of the starting material and so the reaction was 
quenched through the addition of a sat. NaHCO3 solution (2 mL) and extracted with CH2Cl2 
(3 x 5 mL). The combined organic extracts were dried over MgSO4, gravity filtered from 
inorganic salts and concentrated in vacuo to give a yellow oil. Purification by FCC (gradient 
of CH2Cl2 to 5%MeOH/CH2Cl2) gave the two title compounds, 24a as colorless crystals (44 
mg, 32%) and 26 as a yellow oil (15 mg, 30%). 
Procedure B: To a solution of the amino-diol 24 (297 mg, 0.650 mmol) in dry CH2Cl2 (20 
mL) at 0 
o
C was added Et3N (136 µL, 0.975 mmol), PPh3 (256 mg, 0.975 mmol) and CBr4 
(323 mg, 0.975 mmol). The mixture was stirred at 0 
o
C for 5 min then allowed to warm to 
room temperature for 30 min by which time TLC analysis confirmed full consumption of the 
starting material. The mixture was then poured into water (15 mL) and subsequently 
extracted with CH2Cl2 (3 x 20 mL). The combined extracts were dried (MgSO4), filtered and 
concentrated in vacuo to give a yellow oil. The residue was purified by FCC (3:5 
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EtOAc/hexane) to give 26 as a pale-yellow oil (248 mg, 87%). 24a Rf 0.38 
(5%MeOH/CH2Cl2). [α]
 -2.7 (c 1.00, CHCl3). IR υmax (cm
-1
): 3484, 3400, 3064, 2958, 




H NMR (500 MHz, CDCl3) δ 7.45 – 7.23 (10H, m, 
ArH), 4.98 (2H, d, J = 4.2 Hz, H5, H3՛), 4.78 (2H, dd, J = 44.9, 10.7 Hz, OCH2Ph), 4.53 (2H, 
dd, J = 25.1, 11.7 Hz, OCH2Ph), 4.38 (1H, d, J = 4.8 Hz, H4), 4.14 (1H, s, H1), 4.10 – 3.90 
(2H, m, H3, H1՛), 3.85 (3H, dd, J = 16.9, 7.3 Hz, H4՛, H2՛), 3.00 (6H, d, J = 19.3 Hz, 2 x 
OMS), 2.78 (1H, d, J = 7.2 Hz, OH), 1.49 (3H, s, CH3), 1.36 (3H, d, J = 6.8 Hz, H1՛՛), 1.28 
(3H, s, CH3). 
13
C NMR (125 MHz, CDCl3) δ 137.7 (ArC), 137.5 (ArC), 128.7 (2 x ArCH), 
128.7 (2 x ArCH), 128.5 (2 x ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.0 (2 x ArCH), 111.9 
(C7), 86.3 (C4), 81.8 (C5), 79.5 (C3՛), 76.7 (C1), 74.3 (OCH2Ph), 73.7 (OCH2Ph), 71.1 
(C2՛), 68.8 (C3 or C1՛), 68.5 (C4՛), 63.6 (C3 or C1՛), 38.7 (OMs), 36.8 (OMs), 26.6 (CH3), 
24.4 (CH3), 21.8 (C1՛՛). LRESIMS m/z 636 [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+ 
Calcd 
for C28H39NO10S2Na 636.1913; Found 636.1913. 26 Rf 0.25 (5:95 MeOH/CH2Cl2). 
[α]
+15.6 (c 1.00, CHCl3). IR υmax (cm
-1
): 3397, 2983, 1520, 1493, 1120, 1066, 866. 
1
H 
NMR (500 MHz, CDCl3) δ 7.44 – 7.16 (10H, m, ArH), 4.68 (1H, d, J = 12.0 Hz, OCH2Ph), 
4.63 (1H, dd, J = 6.8, 3.5 Hz, H8b), 4.58 (1H, d, J = 11.9 Hz, OCH2Ph), 4.49 (1H, d, J = 11.9 
Hz, OCH2Ph), 4.45 (1H, d, J = 12.0 Hz, OCH2Ph), 4.28 (1H, s, H8), 4.17 (1H, t, J = 7.3 Hz, 
H3a), 3.83 (1H, s, H7), 3.63 (1H, d, J = 3.4 Hz, H8a), 3.45 (1H, dd, J = 9.2, 2.8 Hz, H1՛), 
3.35 (1H, dd, J = 9.2, 4.0 Hz, H1՛), 3.31 – 3.25 (2H, m, H4, H6), 1.49 (3H, s, C2-CH3), 1.28 
(6H, s, C2-CH3, H1՛՛). 
13
C NMR (125 MHz, CDCl3) δ 137.7 (ArC), 137.2 (ArC), 128.5 
(ArC), 128.0 (ArC), 128.0 (ArC), 127.8 (ArC), 127.4 (ArC), 114.1 (C2), 88.4 (C7), 85.7 
(C3a), 83.8 (C8b), 78.3 (C8a), 76.3 (C8), 73.8 (OCH2Ph), 73.1 (C1՛), 71.5 (OCH2Ph), 63.7 
(C4 or C6), 63.5 (C4 or C6), 27.8 (C2-CH3), 25.6 (C2-CH3), 14.9 (C1՛՛). LRESIMS m/z 440 
(100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 




trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (27). Triethylamine (7.7 µL, 
0.0553 mmol) was slowly added to a solution of 25 (23 mg, 0.0503 mmol) in anhydrous DCE 
(8 mL) at 0 
o
C under a N2 atmosphere. Whilst stirring, a 0.13M solution of methanesulfonyl 
chloride in anhydrous CH2Cl2 (423 µL, 0.0553 mmol) was slowly added dropwise to the 
reaction mixture. After stirring at 0 
o
C for 30 min, the reaction mixture was quenched through 
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the addition of a sat. NaHCO3 solution (2 mL) and extracted with CH2Cl2 (3 x 5 mL) 
followed by concentration in vacuo. The crude brown oil was then dissolved in DCE 
followed by the addition of triethylamine (7.7 µL, 0.0553 mmol). The reaction mixture with 
was then heated at 80 
o
C for 20 h. TLC analysis confirmed full consumption of the starting 
material and so the reaction was quenched through the addition of NaHCO3 solution (10 mL) 
and extracted with CH2Cl2 (3 x 10 mL). The combined extracts were dried (MgSO4), filtered 
and concentrated in vacuo to give a yellow oil. Purification by FCC (5:95 MeOH/CH2Cl2) 
gave pyrrolizidine 27 as a clear film (19 mg, 87%). Rf 0.38 (3:97 MeOH/CH2Cl2). 
[α]
+28.7 (c 1.00, CHCl3). IR υmax (cm
-1
): 3390, 3033, 2983, 1544, 1502, 1065, 864. 
1
H 
NMR (500 MHz, CDCl3) δ 7.38 – 7.22 (10H, m, ArH), 4.68 (1H, d, J = 11.9 Hz, OCH2Ph), 
4.63 (1H, t, J = 5.5 Hz, H8b), 4.57 – 4.49 (4H, m, OCH2Ph, H8, H3a), 4.46 (1H, d, J = 12.1 
Hz, OCH2Ph), 4.02 (1H, dd, J = 6.4, 4.1 Hz, H7), 3.60 (1H, dt, J = 6.8, 3.6 Hz, H6), 3.52 
(1H, dd, J = 10.1, 4.1 Hz, H1՛), 3.47 (1H, dd, J = 10.1, 3.2 Hz, H1՛), 3.24 (1H, dd, J = 5.0, 
3.6 Hz, H8a), 3.06 (1H, dt, J = 7.0, 4.1 Hz, H4), 1.48 (3H, s, C2-CH3), 1.33 – 1.27 (6H, m, 
C2-CH3, H1՛՛). 
13
C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 138.2 (ArC), 128.4 (ArCH), 
128.3 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.5 (ArCH), 112.0 (C2), 91.2 
(C7), 85.1 (C3a or C8), 80.2 (C8b), 74.7 (C3a or C8), 74.4 (C8a), 73.4 (OCH2Ph), 72.0 
(OCH2Ph), 69.8 (C1՛), 62.9 (C6), 57.6 (C4), 26.1 (C2-CH3), 24.0 (C2-CH3), 12.0 (C1՛՛). 
LRESIMS m/z 462 (100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+
 Calcd for 
C26H33NO5Na 462.2256; Found 462.2247.  
 
General method for O-Benzyl and acetonide deprotection 
 
(1R,2R,3R,5R,6R,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-
pyrrolizine-1,2,6,7-tetraol [(+)-7-epi-hyacinthacine C5] (8). To a nitrogen purged solution 
of compound 26 (15 mg, 0.034 mmol) in MeOH (3 mL) was added PdCl2 (9 mg, 0.051 
mmol). A balloon of H2 was attached to the system, and the reaction mixture was stirred at rt 
for 24 h. After LRESIMS analysis confirmed full consumption of the starting material, the 
mixture was filtered through a pad of celite and washed with additional MeOH (6 mL). The 
combined filtrates were concentrated in vacuo to give a yellow film. An Amberlyst A-26 
resin (0.750 g) basic ion-exchange chromatography column, was prepared by mixing the 
resin with a 15% aqueous ammonia solution (v/v) and allowing it to stand for 15 min 
followed by washing the column with distilled water until a pH close to 7 was achieved. The 
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compound was dissolved in distilled water (2 mL) and held on the column for 15 min before 
its elution with water (3 x 3 mL). Concentration in vacuo provided (+)-7-epi-hyacinthacine 
C5 8 (6.6 mg, 88%) as a colorless film. [α]
+5.4 (c 1.00, H2O). IR υmax (cm
-1
): 3362, 1637, 
1074, 1055. 
1
H NMR (500 MHz, D2O) δ 4.15 (1H, dd, J = 5.0, 2.7 Hz, H7), 3.94 (1H, t, J = 
7.3 Hz, H2), 3.90 – 3.78 (2H, m, H1, H6), 3.71 – 3.59 (2H, m, H8), 3.21 – 3.13 (2H, m, H7a, 
H5), 3.10 (1H, dt, J = 7.2, 5.0 Hz, H3), 1.26 (3H, d, J = 7.0 Hz, H9). 
13
C NMR (125 MHz, 
D2O) δ 78.5 (C1 or C6), 77.9 (C2), 75.9 (C6 or C1), 73.6 (C7), 72.6 (C7a), 62.9 (C8), 62.2 
(C3), 58.8 (C5), 13.2 (C9). LRESIMS m/z 242 (100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: 
[M+Na]
+
 Calcd for C9H17NO5Na 242.1004; Found 242.1014.  
 
(1R,2R,3R,5R,6S,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-
pyrrolizine-1,2,6,7-tetraol [(–)-6-epi-hyacinthacine C5] (9). (–)-6-Epi-hyacinthacine C5 9 
was synthesized by the general method for O-benzyl deprotection from 27 (10 mg, 0.0227 
mmol). The crude product was filtered through a pad of celite and washed with additional 
MeOH (6 mL). The combined filtrates were concentrated in vacuo returning a yellow film. 
The compound was then isolated through basic ion-exchange chromatography followed by 
concentration in vacuo providing the title compound as a colorless film (4.8 mg, 98%). 
[α]
-7.2 (c 1.00, H2O). IR υmax (cm
-1
): 3300, 2909, 1420, 1098, 1055. 
1
H NMR (500 MHz, 
D2O) δ 4.39 – 4.28 (2H, m, H1, H7), 4.03 (1H, t, J = 4.5 Hz, H6), 3.91 (1H, t, J = 8.3 Hz, 
H2), 3.67 (2H, d, J = 4.8 Hz, H8), 3.38 (1H, p, J = 4.8 Hz, H3), 3.31 (1H, t, J = 7.6 Hz, H7a), 
3.24 (1H, dt, J = 7.0, 5.4 Hz, H5), 1.25 (3H, d, J = 7.1 Hz, H9). 
13
C NMR (125 MHz, D2O) δ 
78.5 (C2), 74.8 (C6), 74.4 (C1), 70.8 (C7), 67.5 (C7a), 63.1 (C8), 62.2 (C3), 57.2 (C5), 10.9 
(C9). LRESIMS m/z 220 (100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+
 Calcd for 
C9H18NO5 220.1185; Found 220.1211.  
 
General method for O-benzylation  
 
(3aR,4R,6R,7R,8R,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4-
trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (44). To a solution of compound 26 
(19 mg, 0.043 mmol) in THF (5 mL) at 0 
o
C, was slowly added sodium hydride (2.6 mg, 
0.065 mmol 60% dispersion in mineral oil). The reaction mixture was then heated at reflux 
under a nitrogen atmosphere for 5 min, and then cooled to rt. Benzyl bromide (6.1 µL, 0.052 
mmol) and TBAI (2.4 mg, 0.0065 mmol) were then added and the mixture was heated at 
Page 38 of 63
ACS Paragon Plus Environment
































































reflux for 15 min. By this time, TLC analysis had confirmed full consumption of the starting 
material. The reaction mixture was cooled to 0 
o
C, and quenched by the dropwise addition of 
water (10 mL). The mixture was extracted with diethyl ether (3 x 10 mL) and the combined 
extracts were dried (MgSO4), filtered and concentrated in vacuo. The resultant brown oil was 
then purified by FCC (gradient of 3:20 EtOAc/hexane to 1:5 EtOAc/hexane) to afford 
product 44 as a clear oil (21 mg 89%). Rf 0.50 (1:4 EtOAc/hexane). [α]
+85.5 (c 1.00, 
CHCl3). IR υmax (cm
-1
): 2980, 1682, 1374, 1247, 1055. 
1
H NMR (500 MHz, CDCl3) δ 7.50 – 
7.10 (15H, m, ArH), 4.60 (1H, dd, J = 6.9, 3.7 Hz, H8b) 4.57 – 4.34 (6H, m, OCH2Ph), 4.21 
(1H, t, J = 6.8 Hz, H3a), 4.02 (1H, s, H8), 3.99 (1H, s, H7), 3.66 (1H, t, J = 2.7 Hz, H8a), 
3.48 – 3.20 (3H, m, H1՛, H6, H4), 1.50 (3H, s, C2-CH3), 1.29 (6H, s, C2-CH3, H1՛՛). 
13
C 
NMR (125 MHz, CDCl3) δ 138.39 (ArC), 138.11 (ArC), 137.97 (ArC), 128.41 (ArCH), 
128.36 (ArCH), 128.32 (ArCH), 127.69 (ArCH), 127.64 (ArCH), 127.60 (ArCH), 127.57 
(ArCH), 127.55 (ArCH), 113.95 (C2), 86.40 (C3a), 85.79 (C7), 84.89 (C8), 83.58 (C8b), 
74.44 (C8a), 73.19 (OCH2Ph), 72.65 (C1՛), 71.26 (OCH2Ph), 71.20 (OCH2Ph), 62.89 (C4), 
62.66 (C6), 27.71 (C2-CH3), 25.63 (C2-CH3), 15.36 (C1՛՛). LRESIMS m/z 530 (100%) 
[M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C33H40NO5 530.2906; Found 530.2923. 
 
(3aS,4R,6R,7R,8R,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4-
trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (45). Compound 45 was 
synthesized from 27 (24 mg, 0.055 mmol) by the general method for O-benzylation. The 
product was purified by FCC (1:4 EtOAc/hexane) to give the desired compound as an orange 
oil (23 mg, 78%). Rf 0.50 (5:95 MeOH/CH2Cl2). [α]
+5.9 (c 1.00, CHCl3). IR υmax (cm
-1
): 
2995, 1679, 1443, 1256, 1055, 683. 
1
H NMR (500 MHz, CDCl3) δ7.39 – 7.21 (15H, m, 
ArH), 4.61 (1H, d, J = 11.9 Hz, OCH2Ph), 4.56 – 4.44 (7H, m, OCH2Ph, H8b, H3a), 4.39 
(1H, t, J = 4.1 Hz, H8), 4.17 (1H, dd, J = 6.1, 4.2 Hz, H7), 3.59 (1H, dd, J = 5.8, 3.9 Hz, H6), 
3.49 (2H, qd, J = 10.1, 4.2 Hz, H1՛), 3.31 (1H, t, J = 4.0 Hz, H8a), 3.02 (1H, dt, J = 7.0, 2.8 
Hz, H4), 1.49 (3H, s, C2-CH3), 1.33 – 128 (6H, m, C2-CH3 and H1՛՛). 
13
C NMR (125 MHz, 
CDCl3) δ 138.8 (ArC), 138.5 (ArC), 138.4 (ArC), 128.3 (ArCH), 128.3 (ArCH), 128.2 
(ArCH), 127.9 (ArCH), 127.82 (ArCH), 127.78 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 127.3 
(ArCH), 112.0 (C2), 89.3 (C7), 85.5 (C3a or C8b), 82.0 (C8), 80.7 (C3a or C8b), 73.3 
(OCH2Ph), 72.0 (OCH2Ph), 71.9 (OCH2Ph or C8a), 71.7 (OCH2Ph or C8a), 70.1 (C1՛), 62.2 
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(C6), 57.3 (C4), 26.3 (C2-CH3), 24.2 (C2-CH3), 12.1 (C1՛՛). LRESIMS m/z 530 (100%) 
[M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C33H40NO5 530.2906; Found 530.2930. 
 
General method for hydrolysis of an acetonide 
 
 (1S,2R,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3-
methylhexahydro-1H-pyrrolizine-1,2-diol (46). To a solution of 44 (22 mg, 0.042 mmol) in 
EtOH/H2O (1/9, 5 mL), was added 5 N HCl (0.5 mL). The mixture was stirred at room 
temperature for 4 h by which time TLC analysis confirmed the consumption of starting 
material. The reaction mixture was then neutralized by the addition of a saturated solution of 
NaHCO3 until a pH of 7 was achieved. The solution was then evaporated to 5 mL under 
reduced pressure and extracted with EtOAc (3 x 15 mL), the combined extracts were washed 
with saturated NaCl (15 mL), dried (MgSO4), filtered and concentrated in vacuo to give a 
brown oil. Purification by FCC (5:95 MeOH/CH2Cl2) gave the title compound 46 as a pale-
yellow oil (20 mg, 98%). Rf 0.20 (5:95 MeOH/CH2Cl2). [α]
-38.9 (c 1.00, CHCl3). IR υmax 
(cm
-1
): 3324, 3089, 2922, 2853, 1600, 1496, 1095, 608. 
1
H NMR (500 MHz, CDCl3) δ 7.41 – 
7.16 (15H, m, ArH), 4.68 – 4.40 (6H, m, OCH2Ph), 4.01 (1H, t, J = 3.7 Hz, H2), 3.98 (1H, t, 
J = 5.0 Hz, H7), 3.91 (1H, t, J = 3.8 Hz, H1), 3.70 (1H, t, J = 6.0 Hz, H6), 3.50 (1H, t, J = 4.3 
Hz, H7a), 3.44 (2H, d, J = 6.5 Hz, H1՛), 3.32 (1H, td, J = 6.5, 3.6 Hz, H3), 3.22 (1H, p, J = 
6.9 Hz, H5), 3.08 (2H, bs, OH), 1.19 (3H, d, J = 6.9 Hz, H1՛՛). 
13
C NMR (125 MHz, CDCl3) 
δ 138.22 (ArC), 137.97 (ArC), 137.94 (ArC), 128.36 (ArCH), 128.29 (ArCH), 127.68 
(ArCH), 127.65 (ArCH), 127.62 (ArCH), 127.53 (ArCH), 86.01 (C1), 85.37 (C2), 77.11 
(C6), 74.76 (C7a), 73.83 (C7), 73.19 (OCH2Ph), 72.15 (OCH2Ph), 71.85 (C1՛), 71.53 





Calcd for C30H36NO5 490.2593; Found 490.2577. 
 
(1R,2S,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3-
methylhexahydro-1H-pyrrolizine-1,2-diol (47). Compound 47 was synthesized from 45 (50 
mg, 0.094 mmol) using the general method for hydrolysis of an acetonide. The product was 
purified by FCC (5:95 MeOH/CH2Cl2) to give the desired product as a brown oil (39 mg, 
85%). Rf 0.26 (5:95 MeOH/CH2Cl2). [α]
+24.4 (c 1.00, CHCl3). IR υmax (cm
-1
): 3334, 
3063, 2926, 1623, 1453, 1368, 1027, 737. 
1
H NMR (500 MHz, CDCl3) δ 7.37 – 7.21 (15H, 
m, ArH), 4.60 – 4.43 (6H, m, OCH2Ph), 4.31 (1H, t, J = 3.3 Hz, H1), 4.24 (1H, dd, J = 7.5, 
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4.8 Hz, H7), 4.11 (1H, t, J = 3.1 Hz, H2), 3.89 (1H, t, J = 4.7 Hz, H6), 3.78 – 3.70 (2H, m, 
H7a, H3), 3.42 (2H, dd, J = 7.1, 3.3 Hz, H1՛), 3.37 (1H, dd, J = 7.1, 4.6 Hz, H5), 1.25 (3H, d, 
J = 7.0 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 138.1 (ArC), 137.0 (ArC), 
128.6 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.10 (ArCH), 128.08 (ArCH), 127.70 
(ArCH), 127.69 (ArCH), 127.6 (ArCH), 85.3 (C2), 82.5 (C1), 75.0 (C6), 73.3 (OCH2Ph), 
72.9 (C7), 72.0 (OCH2Ph), 71.9 (OCH2Ph), 71.6 (C7a or C3), 71.6 (C1՛), 62.4 (C7a or C3), 
58.6 (C5), 11.9 (C1՛՛). LRESIMS m/z 490 (100%) [M+H]+. HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C30H36NO5 490.2593; Found 490.2585. 
 
General method for the formation of a cyclic sulfate 
 
(3aR,4R,6R,7R,8R,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4-
methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (48). To a solution 
of the diol 46 (48 mg, 0.098 mmol) in anhydrous CH2Cl2 (5 mL) under a nitrogen atmosphere 
was added at 0 
o
C, Et3N (35 µL, 0.25 mmol) then SOCl2 (12 µL, 0.15 mmol) dropwise. After 
stirring at 0 
o
C for 1 h, TLC analysis confirmed the consumption of starting material. The 
reaction was quenched with water (10 mL) and the mixture was extracted with CH2Cl2 (3 x 
15 mL). The combined extracts were dried (MgSO4), filtered and concentrated in vacuo to 
give 48 as a brown oil (54 mg) which was used for the next step without further purification. 





xy)methyl)-4-methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (49). 
Compound 49 was synthesized from the diol 47 (40 mg, 0.082 mmol) by using the general 
method for the synthesis of a cyclic sulfate. The resultant crude brown oil (45 mg) was used 




General method for ring opening of cyclic sulfates with benzoate 
 
(1S,2S,3R,5R,6R,7R,7aR)-6,7-bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3-
methylhexahydro-1H-pyrrolizin-2-yl benzoate (50) and (1R,2R,3R,5R,6R,7R,7aS)-6,7-
Bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3-methylhexahydro-1H-pyrrolizin-1-yl 
benzoate (51). To a solution of the cyclic sulfate 48 (61 mg, 0.11 mmol) in dry DMSO (1 
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mL) was added benzoic acid (67 mg, 0.55 mmol) and cesium carbonate (180 mg, 0.55 
mmol). The reaction mixture was stirred under a nitrogen atmosphere at 50 
o
C for 20 h. After 
LRESIMS confirmed the consumption of starting material, a mixture of THF (2 mL), 
distilled water (0.75 mL) and conc. H2SO4 (0.25 mL) was added to the reaction and stirred at 
60 
o
C for 20 h. The reaction mixture was then neutralized with saturated NaHCO3 until a pH 
of 7 was achieved, followed by extraction with CH2Cl2 (3 x 15 mL). The combined extracts 
were dried (MgSO4), filtered and concentrated in vacuo to give a brown oil. Purification by 
FCC (1:1 EtOAc/hexane) gave an inseparable mixture of 50 and 51 (32 mg, 49 %, 1:4 by 
1
H 
NMR analysis). This mixture was subsequently subject to O-benzoyl hydrolysis (see General 
method below) to afford 54 (5 mg, 19%) and 55 (20 mg, 75%) which were separable by FCC 





methylhexahydro-1H-pyrrolizin-2-yl benzoate (52) and (1S,2S,3R,5R,6R,7R,7aS)-6,7-
Bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3-methylhexahydro-1H-pyrrolizin-1-yl 
benzoate (53). Compounds 52 and 53 were synthesized from the cyclic sulfate 49 (45 mg, 
0.0817 mmol) using the general method for ring opening of cyclic sulfates with benzoate. 
Purification by FCC (2:3 EtOAc/hexane) gave pure samples of the two title compounds, 52 
(11 mg, 23%) and 53 (19 mg, 39%), as clear yellow films. 52 Rf 0.56 (2:3 EtOAc/hexane). 
[α]
+13.4 (c 1.00, CHCl3). IR υmax (cm
-1
): 3340, 3063, 2922, 1707, 1496, 1154, 1027, 583. 
1
H NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.7 Hz, o-Bz), 7.57 (1H, t, J = 7.4 Hz, p-Bz), 
7.44 (2H, t, J = 7.7 Hz, m-Bz), 7.38 – 7.20 (15H, m, ArH), 5.04 (1H, dd, J = 7.3, 4.5 Hz, H6), 
4.69 – 4.43 (6H, m, OCH2Ph), 4.30 – 4.19 (2H, m, H1, H7), 4.14 (1H, s, H2), 3.87 (1H, dd, J 
= 7.1, 2.5 Hz, H7a), 3.55 (1H, d, J = 6.9 Hz, H3), 3.45 (1H, d, J = 9.4 Hz, H1՛), 3.42 – 3.30 
(2H, m, H1՛, H5), 1.32 (3H, d, J = 7.0 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 166.7 (CO), 
138.3 (ArC), 138.0 (ArC), 137.2 (ArC), 133.2 (ArC), 129.9 (ArCH), 129.8 (ArCH), 128.7 
(ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.7 
(ArCH), 127.7 (ArCH), 127.6 (ArCH), 86.3 (C6), 85.2 (C2), 82.5 (C1), 77.2 (C7), 73.2 
(OCH2Ph), 72.2 (C1՛), 71.8 (OCH2Ph), 71.7 (OCH2Ph), 71.4 (C7a), 62.5 (C3), 58.4 (C5), 
15.3 (C1՛՛). LRESIMS m/z 594 (100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for 
C37H40NO6 594.2856; Found 594.2877. 53 Rf 0.39 (2:3 EtOAc/hexane). [α]
+9.0 (c 1.00, 
CHCl3). IR υmax (cm
-1
): 3330, 3112, 2970, 1646, 1453, 1095, 906, 565. 
1
H NMR (500 MHz, 
CDCl3) δ 8.02 (2H, d, J = 7.8 Hz, o-Bz), 7.57 (1H, t, J = 7.4 Hz, p-Bz), 7.43 (2H, t, J = 7.6 
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Hz, m-Bz), 7.37 – 7.22 (15H, m, ArH), 5.16 (1H, d, J = 3.2 Hz, H7), 4.63 – 4.42 (7H, m, 
OCH2Ph, H1), 4.14 (1H, s, H2), 4.02 (1H, d, J = 3.7 Hz, H6), 3.84 (1H, t, J = 7.8 Hz, H3), 
3.66 (1H, d, J = 3.2 Hz, H7a), 3.58 (1H, dt, J = 10.6, 5.1 Hz, H5), 3.44 (2H, d, J = 7.8 Hz, 
H1՛), 1.38 (3H, d, J = 7.0 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 166.3 (CO), 138.4 (ArC), 
137.9 (ArC), 136.5 (ArC), 133.2 (ArC), 130.0 (ArCH), 129.8 (ArCH), 129.7 (ArCH), 128.6 
(ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.3 (ArCH), 128.24 (ArCH), 128.20 (ArCH), 127.7 
(ArCH), 127.6 (ArCH), 127.5 (ArCH), 85.6 (C2), 85.3 (C1), 85.1 (C7), 79.5 (C6), 76.4 
(C7a), 73.2 (OCH2Ph), 72.7 (C1՛), 72.0 (OCH2Ph), 71.6 (OCH2Ph), 63.5 (C3), 61.2 (C5), 
11.4 (C1՛՛). LRESIMS m/z 594 (100%) [M+H]+. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C37H40NO6 594.2856; Found 594.2880. 
 
General method for O-Benzoyl hydrolysis 
 
(1R,2R,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3-
methylhexahydro-1H-pyrrolizine-1,2-diol (53). To a solution of 52 (11 mg, 0.017 mmol) in 
MeOH (5 mL) was added solid K2CO3 (4.1 mg, 0.026 mmol). After stirring at 40 
o
C for 2 h, 
all volatiles were evaporated and the residue was dissolved in EtOAc. The solution was then 
washed with water (3 x 5 mL) and brine (5 mL) then dried (MgSO4), filtered and 
concentrated in vacuo to give a brown oil. The crude product was then purified by FCC (5:95 
MeOH/CH2Cl2) to give 54 as a brown film (7.5 mg, 90%). Rf 0.20 (5:95 MeOH/CH2Cl2). 
[α]
-25.4 (c 1.00, CHCl3). IR υmax (cm
-1




H NMR (500 MHz, CDCl3) δ 7.43 – 7.10 (15H, m, ArH), 4.67 – 4.36 (6H, m, OCH2Ph), 
4.19 (1H, t, J = 2.6 Hz, H1), 4.09 (1H, s, H2), 3.99 (1H, dd, J = 7.5, 4.7 Hz, H7), 3.89 (1H, 
dd, J = 7.5, 2.8 Hz, H7a), 3.67 (1H, dd, J = 7.5, 4.6 Hz, H6), 3.53 – 3.40 (3H, m, H3, H1՛), 
3.17 (1H, p, J = 6.5, 6.1 Hz, H5), 2.02 (1H, bs, OH), 1.29 (3H, d, J = 6.9 Hz, H1՛՛). 13C NMR 
(125 MHz, CDCl3) δ 138.2 (ArC), 137.9 (ArC), 137.0 (ArC), 128.6 (ArCH), 128.4 (ArCH), 
128.4 (ArCH), 128.13 (ArCH), 128.07 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.7 (ArCH), 
127.7 (ArCH), 85.0 (C2), 84.4 (C6), 82.3 (C1), 79.4 (C7), 73.3 (OCH2Ph), 72.1 (C1՛), 71.9 
(OCH2Ph), 71.8 (OCH2Ph), 70.3 (C7a), 62.6 (C3), 60.3 (C5), 14.7 (C1՛՛). LRESIMS m/z 490 
(100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+
 Calcd for C30H36NO5 490.2593; Found 
490.2608. 
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methylhexahydro-1H-pyrrolizine-1,2-diol (55). Compound 55 was synthesized from 
benzoate 53 (15 mg, 0.0253 mmol) using the general method for O-benzoyl deprotection, 
except that the reaction was stirred at rt for 1 h. The crude brown oil was purified by FCC 
(5:95 MeOH/CH2Cl2) to give the product as a clear brown film (10 mg, 83%). Rf 0.14 (5:95 
MeOH/CH2Cl2). [α]
-1.62 (c 1.00, CHCl3). IR υmax (cm
-1
): 3389, 2890, 1654, 1489, 1054. 
1
H NMR (500 MHz, CDCl3) δ 7.45 – 7.17 (15H, m, ArH), 4.64 – 4.43 (6H, m, OCH2Ph), 
4.14 – 4.08 (3H, m, H7, H1, H2), 3.81 (1H, dd, J = 3.8, 1.8 Hz, H6), 3.73 (1H, td, J = 6.9, 3.0 
Hz, H3), 3.65 (1H, q, J = 5.2, 4.5 Hz, H5), 3.56 (1H, t, J = 3.1 Hz, H7a), 3.44 (2H, d, J = 1.6 
Hz, H1՛), 1.28 (3H, d, J = 7.0 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 137.8 
(ArC), 136.9 (ArC), 128.6 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.12 (ArCH), 128.10 
(ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 85.8 (C1 or C7 or C2), 85.0 (C1 or C7 
or C2), 81.5 (C6), 81.3 (C1 or C7 or C2), 76.8 (C7a), 73.2 (OCH2Ph), 72.3 (OCH2Ph), 71.8 
(OCH2Ph), 71.6 (C1՛), 62.5 (C3), 60.1 (C5), 11.4 (C1՛՛). LRESIMS m/z 490 (100%) [M+H]
+
. 
HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C30H36NO5 490.2593; Found 490.2615. 
 
(1R,2R,3R,5R,6R,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-
pyrrolizine-1,2,6,7-tetraol [(+)-1-epi-hyacinthacine C4 (Corrected structure for (+)-
hyacinthacine C5)] (7).
21
 (+)-1-Epi-hyacinthacine C4 7 was synthesized by the general 
method of O-benzyl deprotection from 54 (7 mg, 0.0143 mmol). The crude product was 
filtered through a pad of celite and washed with additional MeOH (6 mL). The combined 
filtrates were concentrated in vacuo returning a yellow film. The title compound was then 
isolated, through basic ion-exchange chromatography followed by concentration in vacuo, as 
a colorless film (3 mg, 95%). [α]
+5.25 (c 1.00, H2O). IR υmax (cm
-1
): 3296, 2928, 1602, 
1430, 1072. 
1
H NMR (500 MHz, D2O) δ 4.14 (2H, app. q, J = 7.7 Hz, H7 and H1), 3.94 (1H, 
t, J = 7.8 Hz, H2), 3.74 (1H, t, J = 7.7 Hz, H6), 3.66 (2H, dd, J = 9.5, 4.7 Hz, H8), 3.38 (1H, 
t, J = 7.6 Hz, H7a), 3.14 (1H, td, J = 9.1, 4.7, 4.0 Hz, H3), 2.95 (1H, dq, J = 6.6, 7.4 Hz, H5), 
1.27 (3H, d, J = 6.7 Hz, H9). 
13
C NMR (125 MHz, D2O) δ 78.8 (C6), 78.1 (C2), 75.2 (C1), 
74.9 (C7), 66.3 (C7a), 62.8 (C8), 62.1 (C3), 58.4 (C5), 12.8 (C9). LRESIMS m/z 220 (100%) 
[M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C9H18NO5 220.1185; Found 220.1201. 
 
(1R,2R,3R,5R,6S,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-
pyrrolizine-1,2,6,7-tetraol [(+)-6,7-di-epi-hyacinthacine C5] (10). (+)-6,7-di-epi-
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hyacinthacine C5 10 was synthesized by the general method of O-benzyl deprotection from 
55 (10 mg, 0.0204 mmol). The crude product was filtered through a pad of celite and washed 
with additional MeOH (6 mL). The combined filtrates were concentrated in vacuo returning a 
green film. The title compound was then isolated, through basic ion-exchange 
chromatography followed by concentration in vacuo, as a colorless film (3.4 mg, 75%). 
[α]
+6.8 (c 1.00, H2O). IR υmax (cm
-1
): 3290, 2943, 1593, 1375, 1208, 1079. 
1
H NMR (500 
MHz, D2O) δ 4.18 (1H, t, J = 4.0 Hz, H7), 4.07 – 3.97 (2H, m, H6, H1), 3.90 (1H, t, J = 8.1 
Hz, H2), 3.67 (2H, t, J = 4.0 Hz, H8), 3.41 (1H, dt, J = 11.7, 5.7 Hz, H5), 3.33 (1H, dt, J = 
9.0, 4.9 Hz, H3), 3.07 (1H, dd, J = 8.1, 3.7 Hz, H7a), 1.24 (3H, d, J = 7.1 Hz, H9). 
13
C NMR 
(125 MHz, D2O) δ 79.7 (C6 or C7), 78.6 (C6 or C7), 78.0 (C1), 77.9 (C2), 72.1 (C7a), 62.9 





Calcd for C9H18NO5 220.1185; Found 220.1180. 
 
(1R,2R,3R,5R,6S,7S,7aR)-3-(acetoxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetrayl tetraacetate (56) To a solution of 10 (8 mg, 0.037 mmol) in pyridine (147 
µL, 1.83 mmol) was added acetic anhydride (173 µL, 1.83 mmol) and a crystal of 4-
dimethylaminopyridine. The mixture was stirred at rt for 24 h, by which time LRESIMS 
analysis confirmed full consumption of the starting material. The reaction was quenched 
through the addition of sat. NaHCO3 solution (3 mL) and extracted with CH2Cl2 (3 x 5 mL). 
The combined extracts were dried (MgSO4), filtered and concentrated in vacuo to give an 
orange oil. Purification by FCC (3:97 MeOH/CH2Cl2) gave the pentaacetylated product 56 as 
a pale-yellow film (15 mg, 95%). Rf 0.35 (3:95 MeOH/CH2Cl2). [α]
+12.9 (c 1.00, CHCl3). 
IR υmax (cm
-1
): 2934, 1736, 1432, 1368, 1217, 1033, 886, 603. 
1
H NMR (500 MHz, CDCl3) δ 
5.36 (1H, t, J = 4.8 Hz, H1), 5.24 (1H, t, J = 4.8 Hz, H2), 5.20 (2H, dd, J = 7.6, 3.8 Hz, H6, 
H7), 4.04 (2H, qd, J = 11.3, 5.8 Hz, H1՛), 3.72 – 3.57 (2H, m, J = 6.1 Hz, H3, H5), 3.41 (1H, 
t, J = 4.5 Hz, H7a), 2.14 – 2.05 (15H, m, 5 x AcCH3), 1.25 (3H, d, J = 7.1 Hz, H1՛՛). 
13
C 
NMR (125 MHz, CDCl3) δ 170.8 (CO), 170.2 (CO), 169.9 (CO), 169.7 (CO), 169.6 (CO), 
80.4 (C6), 79.5 (C7), 78.6 (C2), 77.6 (C1), 73.1 (C7a), 65.5 (C1՛), 60.4 (C3), 58.6 (C5), 
20.94 (AcCH3), 20.92 (AcCH3), 20.89 (AcCH3), 20.85 (AcCH3), 20.8 (AcCH3), 11.3 (C1՛՛). 
LRESIMS m/z 430 (100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C19H28NO10 
430.1713; Found 430.1731. 
 
Synthesis of (5S) pyrrolizidines  
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6-ene-2,4-diol (28). Compound 28 was synthesized by the general method for the Petasis 
reaction using (+)-3,4-Di-O-benzyl-α,β-L-xylofuranose
29–31
 (2.00 g, 6.06 mmol), (E)-2-
phenylvinylboronic acid (896 mg, 6.06 mmol) and (R,S)-α-methylallyl amine·HCl
45
 (652 mg, 
6.06 mmol) instead of the enatiomerically pure (R)-amine. The mixture was purified by FCC 
(5:95 MeOH/CH2Cl2) to give inseperable diastereomers as a brown oil (2.00 g, 65%, as a 2:1 
mixture of 1՛S 28 and 1՛R 16 epimers). 1H and 13C NMR spectroscopic data of the formed 1՛S 
epimer matched the corresponding data of compound 16 described above. Rf 0.20 (3:97 
MeOH/CH2Cl2).
 1
H NMR (500 MHz, CDCl3) δ 7.54 – 7.08 (m), 6.48 (1H, d, J = 16.0 Hz, H7 
(16), 6.41 (1H, d, J = 16.0 Hz, H7 (29)), 6.07 (1H, dd, J = 16.0, 8.8 Hz, H6 (16)), 6.00 (1H, 
dd, J = 16.0, 8.9 Hz, H6 (29)), 5.71 (1H, ddd, J = 17.3, 10.3, 7.1 Hz, H2՛ (16)), 5.62 – 5.51 
(1H, m, H2՛ (29)), 5.10 – 4.96 (m), 4.70 – 4.46 (m), 4.10 – 4.04 (m), 3.94 (1H, t, J = 5.3 Hz, 
H4 (16)), 3.88 (1H, t, J = 5.3 Hz, H4 (29)), 3.70 – 3.54 (m), 3.50 (1H, dd, J = 8.9, 5.2 Hz, H1, 
(16)), 3.44 (1H, dd, J = 8.9, 5.8 Hz, H1 (29)), 3.32 – 3.23 (m), 2.88 (s), 1.11 (3H, d, J = 6.4 
Hz, H1՛՛ (16)), 1.06 (3H, d, J = 6.5 Hz, H1՛՛ (29)). 13C NMR (125 MHz, CDCl3) δ 141.9 (C2՛ 
(16)), 141.5 (C2՛ (29)), 138.1 (ArC), 138.0 (ArC), 136.6 (ArC), 136.5 (ArC), 133.4 (C7 (29)), 
133.2 (C7 (16)), 128.6 (ArC), 128.5 (ArC), 128.5 (ArC), 128.43 (ArC), 128.42 (ArC), 128.2 
(ArC), 128.1 (ArC), 127.92 (ArC), 127.85 (ArC), 127.8 (ArC), 127.73 (ArC), 127.71 (ArC), 
126.5 (ArC), 126.4 (ArC), 116.0 (C3՛ (29)), 114.5 (C3՛ (16)), 80.2 (C3 (29)), 80.0 (C3 (16)), 
74.3 (OCH2Ph (16)), 74.2 (OCH2Ph (29)), 73.38 (OCH2Ph (29)), 73.35 (OCH2Ph (16)), 72.9 
(C4 (29)), 72.3 (C4 (16)), 71.3 (C1 (16)), 71.2 (C1 (29)), 70.4 (C2 (29)), 70.1 (C2 (16)), 60.6 
(C5 (29)), 60.3 (C5 (16)), 53.2 (C1՛ (29)), 52.7 (C1՛ (16)), 22.2 (C1՛՛ (29)), 20.2 (C1՛՛ (16)). 





4-((E)-styryl)oxazolidin-2-one (17, 29) and (4R,5R,6S,7S)-6-(benzyloxy)-7-
((benzyloxy)methyl)-3-(but-3-en-2-yl)-5-hydroxy-4-((E)-styryl)-1,3-oxazepan-2-one (18, 
30). A 2 : 1 mixture of 16 and 28 (50 mg, 0.102 mmol) were dissolved in anhydrous CH2Cl2 
(15 mL) and cooled to 0 
o
C under an atmosphere of nitrogen. Triethylamine (28 µL, 0.204 
mmol) was added and after 15 min triphosgene (15.1 mg, 0.051 mmol) was added 
portionwise and the solution was allowed to warm to rt. After stirring for 1 h, TLC analysis 
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confirmed full consumption of the starting material, leading to the subsequent in vacuo 
concentration of the reaction mixture. Purification via FCC (gradient of 1:5 EtOAc/hexane to 
1:1 EtOAc/hexane) produced an inseparable mixture of the four title isomers consisting of the 
oxazolidinones 17, 29 and the oxazepinones 18, 30 as confirmed by 
1
H NMR analysis and 
LRESIMS (43%). Rf 0.65 (1:1 EtOAc/hexane). 
1
H NMR (500 MHz, CDCl3) δ 7.39 – 7.02 
(m), 6.73 – 6.61 (m, H1՛՛՛ (18 and 30)), 6.60 – 6.51 (m, H2՛՛՛ (17 and 29)), 6.41 (d, J = 15.9 
Hz, H2՛՛՛ (18)), 6.34 (d, J = 15.8 Hz, H2՛՛՛ (30)), 6.17 – 6.03 (m, H1՛՛՛ (17 and 29), H2՛ (18)), 
5.93 (ddd, J = 17.4, 10.6, 4.7 Hz, H2՛ (17 and 30)), 5.83 (ddd, J = 17.1, 10.3, 6.5 Hz, H2՛ 
(29)), 5.30 – 5.21 (m), 5.21 – 5.07 (m), 5.07 – 5.00 (m), 4.89 – 4.71 (m), 4.61 – 4.43 (m), 
4.37 – 4.25 (m), 4.11 – 4.03 (m), 4.02 – 3.95 (m), 3.82 (dd, J = 9.5, 6.1 Hz, H1՛՛՛՛ (30)), 3.79 
– 3.71 (m), 3.51 – 3.42 (m), 1.38 (d, J = 7.1 Hz, H1՛՛ (29), 1.34 (d, J = 6.9 Hz, H1՛՛ (30)), 
1.29 (d, J = 7.0 Hz, H1՛՛ (17)), 1.27 (d, J = 6.3 Hz, H1՛՛ (18)). 
13
C NMR (125 MHz, CDCl3) δ 
158.6 (C2 (30)), 158.5 (C2 (18)), 157.0 (C2 (17)), 156.9 (C2 (29)), 139.2 (C2՛ (18)), 138.3 
(C2՛ (30)), 138.2, 137.88, 137.86, 137.8, 137.7, 137.5, 137.5, 136.8, 136.6, 136.4, 135.7, 
135.5, 135.42, 135.39, 131.8, 131.2, 128.8, 128.6, 128.5, 128.4, 128.38, 128.36, 128.2, 
127.91, 127.87, 127.85, 127.7, 127.6, 127.59, 127.56, 127.3, 126.70, 126.67, 126.7, 126.57, 
124.55 (C1՛՛՛ (17)), 124.4 (C1՛՛՛ (29)), 117.3 , 117.2 (C3՛ (17)), 116.1, 116.0 (C3՛ (29)), 78.6, 
78.2 , 77.8 (C5 (17)), 77.4, 76.5 (C1՛՛՛՛ (29)), 76.3 (C1՛՛՛՛ (17)), 74.8, 74.7, 74.1 (OCH2Ph 
(17)), 74.0 (OCH2Ph (29)), 73.4, 73.1 (OCH2Ph (29)), 73.1 (OCH2Ph (17)), 72.6, 72.5, 70.7 
(C3՛՛՛՛ (29)), 70.6 (C3՛՛՛՛ (17)), 68.9 (C2՛՛՛՛ (29)), 68.8 (C2՛՛՛՛ (17)), 68.4, 67.9, 62.1 (C4 
(30)), 61.6 (C4 (18)), 60.1 (C4 (29)), 60.0 (C4 (17)), 55.6 (C1՛ (18)), 55.3 (C1՛ (30)), 51.8 
(C1՛ (29)), 51.7 (C1՛ (17)), 18.4 (C1՛՛ (17)), 17.2 (C1՛՛ (29)), 16.7 (C1՛՛ (30)), 16.0 (C1՛՛ 




Conversion of 18 and 30 to 17 and 29, respectively. DBU (11.1 µL, 0.0745 mmol) 
was added to a solution of the above mixture of oxazolidinones 17, 29 and oxazepinones 18, 
30 (25.5 mg, 0.0497 mmol) in MeOH (3 mL) under a nitrogen atmosphere. After 4 h of 
stirring, TLC analysis confirmed full consumption of the starting materials. The reaction 
mixture was then concentrated in vacuo followed by dissolution in CH2Cl2 (5 mL). The 
solution was then washed with a saturated solution of NH4Cl (2 x 3 mL), dried (MgSO4), 
filtered and concentrated in vacuo. This afforded an inseparable mixture (1:2.5) of 17 and its 
C1՛ epimer 29 (25.3 mg, 99%). No further purification was required based on 
1
H NMR and 
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TLC analysis. Rf 0.65 (1:1 EtOAc/hexane). 
1
H NMR (500 MHz, CDCl3) δ 7.38 – 7.18 (m, 
ArH), 7.17 – 7.04 (m, ArH), 6.61 – 6.52 (m), 6.18 – 6.05 (m), 5.95 (ddd, J = 16.8, 10.4, 5.8 
Hz, H2՛ (17)), 5.84 (ddd, J = 17.0, 10.3, 6.4 Hz, H2՛ (29)), 5.24 – 5.16 (m), 5.14 – 5.07 (m), 
5.06 – 4.99 (m), 4.89 – 4.81 (m), 4.80 – 4.71 (m), 4.62 – 4.53 (m), 4.53 – 4.35 (m), 4.35 – 
4.23 (m), 4.03 – 3.92 (m), 3.80 – 3.72 (m), 3.55 – 3.43 (m), 1.38 (d, J = 7.1 Hz, H1՛՛ (29)), 
1.29 (d, J = 7.0 Hz, H1՛՛ (17)). 13C NMR (125 MHz, CDCl3) δ 157.0 (C2 (17)), 156.9 (C2 
(29)), 138.4 (C2՛ (29)), 138.0, 137.9, 137.0 (C2՛ (17)), 135.7, 135.6 (C2՛՛՛ (29)), 135.5 (C2՛՛՛ 
(29)), 128.9, 128.6, 128.5, 128.02, 127.97, 127.9, 127.8, 127.72, 127.71, 126.79, 126.77, 
124.9 (C2՛՛՛ (17)), 124.7 (C1՛՛՛ (29)), 117.2 (C3՛ (17)), 116.0 (C3՛ (29)), 77.8, 77.4, 76.7, 
76.5, 74.2 (OCH2Ph (17)), 74.1 (OCH2Ph (29)), 73.20 (OCH2Ph (29)), 73.17 (OCH2Ph (17)), 
70.84 (C3՛՛՛՛ (29)) , 70.76 (C3՛՛՛՛ (17)), 69.0 (C2՛՛՛՛ (29)), 68.9 (C2՛՛՛՛ (17)), 60.2 (C4 (29)), 
60.0 (C4 (17)), 51.9 (C1՛ (29)), 51.8 (C1՛ (17)), 18.53 (C1՛՛ (17)), 17.4 (C1՛՛ (29)). LRESIMS 





dihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (20) and (1R,5R,7aR)-1-((1R,2S)-1,3-
bis(benzyloxy)-2-hydroxypropyl)-5-methyl-5,7a-dihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-
one (31). The title compounds 20 and 31 were synthesized from the above mixture of 17 and 
its C1՛ epimer 29 (486 mg, 0.946 mmol), using the general method for ring-closing 
metathesis. The crude black oil was purified by FCC (1:1 EtOAc/hexane) to give pure 





NMR spectroscopic data of the formed product matched the corresponding data of compound 
20 described above. 31 Rf 0.45 (1:1 EtOAc/hexane). [α]
+58.1 (c 1.00, CHCl3). IR υmax 
(cm
-1
): 3340, 2937, 2870, 1643, 1414, 1329, 1210, 1073, 957. 
1
H NMR (500 MHz, CDCl3) δ 
7.39 – 7.22 (10H, m, ArH), 5.97 (1H, dt, J = 6.1, 2.2 Hz, H7), 5.86 (1H, dt, J = 6.0, 1.6 Hz, 
H6), 5.02 (1H, t, J = 7.8 Hz, H1), 4.83 – 4.77 (2H, m, H7a and OCH2Ph), 4.68 (1H, dt, J = 
8.8, 5.5, 4.5, 2.7 Hz, H5), 4.50 (2H, d, J = 2.9 Hz, OCH2Ph), 4.42 (1H, d, J = 11.8 Hz, 
OCH2Ph), 3.88 (1H, q, J = 8.0, 7.3 Hz, H2՛), 3.68 (1H, dd, J = 7.5, 2.2 Hz, H1՛), 3.56 (1H, 
dd, J = 9.2, 6.1 Hz, H3՛), 3.47 (1H, dd, J = 9.2, 6.8 Hz, H3՛), 2.49 (1H, d, J = 8.0 Hz, OH), 
1.22 (3H, d, J = 6.8 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 162.5 (C3), 137.8 (ArC), 137.7 
(ArC), 137.6 (C7), 128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.1 (2 x ArCH), 127.94 (ArCH), 
127.92 (ArCH), 127.82 (2 x ArCH), 124.81 (C6), 78.6 (C1), 77.2 (C1՛), 74.4 (OCH2Ph), 73.4 
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(OCH2Ph), 70.6 (C3՛), 69.2 (C2՛), 65.9 (C7a), 62.7 (C5), 19.6 (C1՛՛). LRESIMS m/z 432 
(100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+




dihydroxy-5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (32). Compound 32 
was synthesized from 31 (151 mg, 0.369 mmol) using the general method for cis-
dihydroxylation. The product was purified by FCC (5:95 MeOH/CH2Cl2) to give small white 
crystals (160 mg, 98%). Rf 0.32 (5:95 MeOH/CH2Cl2). [α]
+36.2 (c 1.00, CHCl3). IR υmax 
(cm
-1




H NMR (500 
MHz, CDCl3) δ 7.44 – 7.16 (10H, m, ArH), 4.94 – 4.87 (2H, m, H1 and OCH2Ph), 4.63 (1H, 
d, J = 11.2 Hz, OCH2Ph), 4.46 (1H, d, J = 11.5 Hz, OCH2Ph), 4.37 (1H, d, J = 11.5 Hz, 
OCH2Ph), 4.33 (1H, dd, J = 7.9, 2.0 Hz, H7a), 3.96 (1H, s, H7), 3.90 – 3.80 (3H, m, H6, H1՛, 
H2՛), 3.64 (1H, p, J = 6.7 Hz, H5), 3.57 – 3.49 (2H, m, H3՛ and OH), 3.37 (1H, dd, J = 9.1, 
6.7 Hz, H3՛), 2.69 (1H, s, OH), 2.61 (1H, d, J = 8.0 Hz, OH), 1.35 (3H, d, J = 6.6 Hz, 
H1՛՛).13C NMR (125 MHz, CDCl3) δ 161.6 (C3), 137.2 (ArC), 137.2 (ArC), 128.8 (ArCH), 
128.7 (ArCH), 128.6 (ArCH), 128.31 (ArCH), 128.27 (ArCH), 128.1 (ArCH), 81.3 (C6, C1՛, 
C2՛), 76.8 (C1), 75.62 (C7a), 74.56 (OCH2Ph), 73.7 (OCH2Ph), 71.8 (C7), 70.9 (C3՛), 69.3 
(C6, C1՛, C2՛), 62.8 (C6, C1՛, C2՛), 58.7 (C5), 19.5 (Me). LRESIMS m/z 466 (100%) 
[M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+ 





Compound 33 was synthesized from 32 (140 mg, 0.317 mmol) by the general method for 
acetonide protection of cis-diols. Purification by FCC (5:95 MeOH/CH2Cl2) returned large 
colorless crystals (150 mg, 98%). Rf 0.56 (5:95 MeOH/CH2Cl2). [α]
+26.05 (c 1.00, 
CHCl3). IR υmax (cm
-1





NMR (500 MHz, CDCl3) δ 7.43 – 7.20 (10H, m, ArH), 5.03 (1H, dd, J = 8.8, 7.0 Hz, H4), 
4.94 (1H, d, J = 11.4 Hz, OCH2Ph), 4.68 (1H, dd, J = 5.2, 3.6 Hz, H3a), 4.59 (1H, d, J = 11.4 
Hz, OCH2Ph), 4.51 (1H, d, J = 11.7 Hz, OCH2Ph), 4.46 – 4.38 (3H, m, OCH2Ph, H8a, H1՛), 
4.22 (1H, q, J = 7.4 Hz, H8), 3.96 (1H, dd, J = 7.1, 3.5 Hz, H3b), 3.89 (1H, q, J = 6.8 Hz, 
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H2՛), 3.58 (1H, dd, J = 9.4, 6.9 Hz, H3՛), 3.43 (1H, dd, J = 9.5, 5.6 Hz, H3՛), 2.34 (1H, d, J = 
7.7 Hz, OH), 1.46 (3H, s, C2-CH3), 1.20 – 1.11 (6H, m, C2-CH3, H1՛՛). 
13
C NMR (125 MHz, 
CDCl3) δ 160.8 (C6), 137.9 (ArC), 137.8 (ArC), 128.7 (ArCH), 128.44 (ArCH), 128.35 
(ArCH), 127.94 (ArCH), 127.86 (ArCH), 127.7 (ArCH), 112.7 (C2), 87.8 (C8a or C1՛), 80.7 
(C3a), 79.2 (C4), 75.5 (C8a or C1՛), 74.0 (OCH2Ph), 73.4 (OCH2Ph), 71.2 (C3՛), 70.5 (C2՛), 
62.4 (C3b), 59.7 (C8), 26.3 (C2-CH3), 24.1 (C2-CH3), 17.7 (C1՛՛). LRESIMS m/z 506 
(100%) [M+Na]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+ 




[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (34). Compound 34 was synthesized from 33 
(113 mg, 0.234 mmol) by the general method for oxozlididnone hydrolysis. The product was 
purified by FCC (5:95 MeOH/CH2Cl2) to give a pale-brown solid (90 mg, 84%). Rf 0.38 (5:95 
MeOH/CH2Cl2). [α]
-2.6 (c 1.00, CHCl3). IR υmax (cm
-1
): 3412, 3030, 2967, 1498, 1352, 
1072, 1051, 647. 
1
H NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (10H, m, ArH), 4.76 (1H, t, J = 
4.0 Hz, H3a), 4.72 (1H, d, J = 11.5 Hz, OCH2Ph), 4.66 (1H, d, J = 11.5 Hz, OCH2Ph), 4.52 
(2H, s, OCH2Ph), 4.36 (1H, d, J = 5.4 Hz, H6a), 4.08 – 3.99 (2H, m, H1՛, H3՛), 3.74 – 3.68 
(2H, m, H4՛, H2՛), 3.58 (1H, dd, J = 9.8, 4.8 Hz, H4՛), 3.28 (1H, q, J = 7.4 Hz, H6), 3.09 (1H, 
dd, J = 9.0, 4.0 Hz, H4), 2.32 (2H, bs, 2 x OH), 1.28 (6H, s, 2 x C2-CH3), 1.03 (3H, d, J = 7.4 
Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 138.0 (ArC), 137.9 (ArC), 128.6 (ArCH), 128.5 
(ArCH), 128.0 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 110.9 (C2), 86.5 (C6a), 
82.4 (C2՛), 81.8 (C3a), 74.0 (OCH2Ph), 73.7 (OCH2Ph), 70.7 (C4՛), 69.8 (C1՛ and C3՛), 61.8 
(C4), 59.1 (C6), 25.8 (C2-CH3), 23.8 (C2-CH3), 16.6 (C1՛՛). LRESIMS m/z 458 (100%) 
[M+H]
+
. HRMS (ESI-TOF) m/z: [M+Na]
+ 
Calcd for C26H36NO6 458.2543; Found 458.2530. 
 
(3aS,4S,6R,7R,8R,8aS,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4-
trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (35). Triethylamine (44 µL, 
0.319 mmol) was slowly added to a solution of 34 (145.7 mg, 0.319 mmol) in anhydrous 
DCE (15 mL) at 0 
o
C under a nitrogen atmosphere. Whilst stirring, a 0.13M solution of 
methanesulfonyl chloride in anhydrous CH2Cl2 (2.45 mL, 0.319 mmol) was slowly added 
dropwise to the reaction mixture. After stirring at 0 
o
C for 30 min, the reaction mixture was 
quenched through the addition of a sat. NaHCO3 solution (2 mL) and extracted with CH2Cl2 
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(3 x 5 mL) followed by concentration in vacuo. The crude brown oil was then dissolved in 
DCE followed by the addition of triethylamine (44 µL, 0.319 mmol). The reaction mixture 
with was then heated at 80 
o
C for 20 h. TLC analysis confirmed full consumption of the 
starting material and so the reaction was quenched through the addition of NaHCO3 solution 
(10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined extracts were dried (MgSO4), 
filtered and concentrated in vacuo to give a yellow oil. Purification by FCC (5:95 
MeOH/CH2Cl2) gave the title compound 35 as a pale-yellow oil (106 mg, 76%). Rf 0.35 (5:95 
MeOH/CH2Cl2). [α]
+29.9 (c 1.00, CHCl3). IR υmax (cm
-1
): 3358, 2981, 2862, 1702, 1643, 
1211, 1089, 1023, 683. 
1
H NMR (500 MHz, CDCl3) δ 7.48 – 7.17 (10H, m, ArH), 4.77 (1H, 
t, J = 6.0 Hz, H8b), 4.72 (1H, d, J = 12.0 Hz, OCH2Ph), 4.67 (1H, t, J = 6.0 Hz, H8), 4.62 – 
4.54 (2H, m, 2 x OCH2Ph), 4.49 (1H, d, J = 12.1 Hz, OCH2Ph), 4.35 (1H, dd, J = 6.1, 3.6 Hz, 
H3a), 3.91 (1H, t, J = 6.5 Hz, H7), 3.54 – 3.46 (3H, m, H1՛, H8a), 3.34 – 3.24 (2H, m, H4, 
H6), 1.51 (3H, s, C2-CH3), 1.31 (3H, s, C2-CH3), 1.08 (3H, d, J = 6.7 Hz, H1՛՛). 
13
C NMR 
(125 MHz, CDCl3) δ 138.5 (ArC), 138.1 (ArC), 128.4 (ArCH), 128.4 (ArCH), 127.8 (ArCH), 
127.7 (ArCH), 127.6 (ArCH), 113.1 (C2), 88.7 (C7), 88.0 (C3a), 80.0 (C8b), 76.0 (C8), 73.4 
(OCH2Ph), 72.4 (OCH2Ph), 72.0 (C1՛), 71.4 (C8a), 67.2 (C6), 64.3 (C4), 26.9 (C2-CH3), 24.5 
(C2-CH3), 19.0 (C1՛՛). LRESIMS m/z 440 (100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C26H34NO5 440.2437; Found 440.2432. 
 
(1R,2S,3S,5R,6R,7R,7aR)-6-(Benzyloxy)-5-((benzyloxy)methyl)-3-
methylhexahydro-1H-pyrrolizine-1,2,7-triol (36). Compound 36 was synthesized from 35 
(20 mg, 0.0456 mmol) using the general method for hydrolysis of an acetonide. The product 
was purified by FCC (5:95 MeOH/CH2Cl2) to give a pale-yellow oil (16 mg, 89%). Rf 0.14 
(5:95 MeOH/CH2Cl2). [α]
+13.0 (c 1.00, CHCl3). IR υmax (cm
-1
): 3357, 2918, 2863, 1653, 
1539, 1120, 1078, 698. 
1
H NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (10H, m, ArH), 4.69 – 
4.59 (2H, m, OCH2Ph), 4.57 – 4.46 (3H, m, OCH2Ph, H1), 4.06 (1H, d, J = 4.3 Hz, H7), 3.96 
(1H, d, J = 2.5 Hz, H2), 3.73 (1H, t, J = 3.5 Hz, H7a), 3.66 (1H, dd, J = 9.2, 3.8 Hz, H6), 3.59 
(1H, dd, J = 9.7, 3.6 Hz, H1՛), 3.51 (1H, dd, J = 9.6, 3.7 Hz, H1՛), 3.21 (1H, q, J = 3.5 Hz, 
H3), 2.78 (1H, dt, J = 12.4, 6.2 Hz, H5), 1.22 (3H, d, J = 6.1 Hz, H1՛՛). 13C NMR (125 MHz, 
CDCl3) δ 137.3 (ArC), 137.0 (ArC), 128.8 (ArCH), 128.7 (ArCH), 128.4 (ArCH), 128.2 
(ArCH), 128.2 (ArCH), 88.5 (C2), 79.5 (C6), 74.9 (C1), 74.7 (C7a), 74.0 (OCH2Ph), 73.0 
(C1՛), 72.5 (OCH2Ph), 71.8 (C7), 70.4 (C3), 66.3 (C5), 19.0 (C1՛՛). LRESIMS m/z 400 
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. HRMS (ESI-TOF) m/z: [M+H]
+ 




pyrrolizine-1,2,6,7-tetraol [(–)-5,6-di-epi-hyacinthacine C5] (11).
15
 (–)-5,6-Di-epi-
hyacinthacine C5 11 was synthesized by the general method of O-benzyl deprotection from 
36 (15 mg, 0.0365 mmol). The crude product was filtered through a pad of celite and washed 
with additional MeOH (6 mL). The combined filtrates were concentrated in vacuo returning a 
yellow film. The title compound was then isolated, through basic ion-exchange 
chromatography followed by concentration in vacuo, as a colorless film (8 mg, 99%). [α]
-
6.9 (c 1.00, H2O). IR υmax (cm
-1
): 3332, 2981, 1623, 1578, 1478, 1065, 699. 
1
H NMR (500 
MHz, D2O) δ 4.33 (1H, t, J = 7.4 Hz, H1), 4.13 (1H, t, J = 4.1 Hz, H7), 3.89 (1H, t, J = 8.7 
Hz, H2), 3.76 – 3.68 (2H, m, H6 and H8), 3.65 (1H, dd, J = 11.9, 4.7 Hz, H8), 3.26 (1H, dt, J 
= 5.7, 2.8 Hz, H7a), 2.84 (1H, dq, J = 12.7, 6.4 Hz, H5), 2.78 (1H, dt, J = 9.1, 4.3 Hz, H3), 
1.20 (3H, d, J = 6.2 Hz, H9). 
13
C NMR (125 MHz, D2O) δ 79.8 (C6), 78.7 (C2), 73.8 (C1), 
71.5 (C3), 70.6 (C7), 68.6 (C7a), 64.0 (C5), 62.2 (C8), 18.3 (C9). LRESIMS m/z 220 (100%) 
[M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+
 Calcd for C9H18NO5 220.1185; Found 220.1176. 
 
(3aS,4S,6R,7R,8R,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-2,2,4-
trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizine (37). Compound 37 was 
synthesized from 35 (115 mg, 0.262 mmol) by the general method for O-benzylation. The 
product was purified by FCC (1:4 EtOAc/hexane) to give a yellow oil (122 mg, 87%). Rf 0.56 
(3:7 EtOAc/hexane). [α]
+19.3 (c 1.00, CHCl3). IR υmax (cm
-1
): 2987, 1557, 1531, 1278, 
1089, 695. 
1
H NMR (500 MHz, CDCl3) δ 7.50 – 7.15 (15H, m, ArH), 4.68 (1H, d, J = 11.8 
Hz, OCH2Ph), 4.61 (1H, t, J = 5.6 Hz, H8b), 4.59 – 4.52 (5H, m, OCH2Ph, H8), 4.47 (1H, d, 
J = 12.2 Hz, OCH2Ph), 4.38 (1H, dd, J = 5.8, 2.6 Hz, H3a), 4.02 (1H, t, J = 6.2 Hz, H7), 3.60 
– 3.48 (2H, m, H1՛, H8a), 3.47 – 3.36 (3H, m, H1՛, H6, H4), 1.51 (3H, s, C2-CH3), 1.31 (3H, 
s, C2-CH3), 1.04 (3H, d, J = 7.0 Hz, H1՛՛). 
13
C NMR (125 MHz, CDCl3) δ 138.9 (ArC), 
138.8 (2 x ArC), 128.6 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.04 
(ArCH), 128.00 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.7 (ArCH), 112.7 (C2), 89.2 
(C3a), 87.1 (C7), 83.3 (C8), 82.0 (C8b), 73.5 (OCH2Ph), 72.6 (OCH2Ph), 72.5 (OCH2Ph), 
72.5 (C1՛), 69.8 (C8a), 66.4 (C6), 62.9 (C4), 27.2 (C2-CH3), 24.6 (C2-CH3), 19.6 (C1՛՛). 
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LRESIMS m/z 530 (100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C33H40NO5 





 Compound 38 was synthesized from 37 
(122 mg, 0.230 mmol) using the general method for hydrolysis of an acetonide. The product 
was purified by FCC (5:95 MeOH/CH2Cl2) to give a brown oil (95 mg, 85%). Rf 0.26 (5:95 
MeOH/CH2Cl2). [α]
+3.5 (c 1.00, CHCl3). IR υmax (cm
-1
): 3397, 2887, 1676, 1592 1479, 
1064, 687. 
1
H NMR (500 MHz, CDCl3) δ 7.48 – 7.07 (15H, m, ArH), 4.61 (1H, d, J = 11.6 
Hz, OCH2Ph), 4.57 – 4.36 (6H, m, OCH2Ph, H1), 4.16 (1H, t, J = 4.0 Hz, H2), 3.95 (1H, t, J 
= 4.3 Hz, H7), 3.81 (1H, t, J = 4.1 Hz, H7a), 3.69 (1H, dd, J = 9.2, 3.9 Hz, H6), 3.51 (2H, d, J 
= 6.5 Hz, H1՛), 3.26 (1H, q, J = 5.8 Hz, H3), 2.84 (1H, p, J = 6.5 Hz, H5), 1.25 (3H, d, J = 
6.2 Hz, H1՛՛). 
13
C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 138.1 (ArC), 137.4 (ArC), 128.8 
(ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.30 (ArCH), 128.28 (ArCH), 128.1 (ArCH), 128.0 
(ArCH), 127.9 (ArCH), 127.9 (ArCH), 84.3 (C2), 82.1 (C1), 79.7 (C6), 73.5 (OCH2Ph), 72.5 
(OCH2Ph), 72.4 (OCH2Ph), 71.9 (C7), 71.1 (C7a), 70.7 (C1՛), 69.5 (C3), 65.4 (C5), 18.7 
C1՛՛). LRESIMS m/z 490 (100%) [M+H]+. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C30H36NO5 490.2593; Found 490.2602. 
 
(3aS,4S,6R,7R,8R,8aS,8bR)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4-
methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (39). Compound 39 
was synthesized from the diol 38 (55 mg, 0.111 mmol) by using the general method for the 
synthesis of a cyclic sulfate. The resultant crude brown oil (61 mg) was used for the next step 





methylhexahydro-1H-pyrrolizin-1-yl benzoate (40) and (1R,2R,3S,5R,6R,7R,7aR)-6,7-
bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3-methylhexahydro-1H-pyrrolizin-2-yl 
benzoate (41). Compounds 40 and 41 were synthesized from the cyclic sulfate 39 (61 mg, 
0.111 mmol) using the general method for ring opening of cyclic sulfates with benzoate. 
Purification by FCC (1:1 diethyl ether/hexane) gave 40 (40 mg, 61%) and 41 (8 mg, 12%) as 
clear films. 40 Rf 0.26 (1:1 diethyl ether/hexane). [α]
-12.2 (c 1.00, CHCl3). IR υmax (cm
-1
): 
3367, 3089, 2946, 1687, 1525, 1167, 1038, 598. 
1
H NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J 
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= 7.7 Hz, o-Bz), 7.60 (1H, t, J = 7.5 Hz, p-Bz), 7.46 (2H, t, J = 7.7 Hz, m-Bz), 7.36 – 7.19 
(15H, m, ArH), 5.13 (1H, t, J = 5.7 Hz, H7), 4.63 – 4.47 (6H, m, OCH2Ph), 4.28 (1H, t, J = 
4.0 Hz, H1), 4.14 (1H, t, J = 3.1 Hz, H2), 3.94 (1H, t, J = 6.7 Hz, H6), 3.73 (1H, t, J = 5.3 Hz, 
H7a), 3.63 (1H, s, OH), 3.52 – 3.45 (2H, q, J = 9.4, 7.4 Hz, H1՛), 3.35 (1H, t, J = 9.2, 4.5 Hz, 
H3), 3.21 (1H, p, J = 6.5 Hz, H5), 1.24 (3H, d, J = 6.2 Hz, H1՛՛). 13C NMR (125 MHz, 
CDCl3) δ 167.8 (CO), 138.4 (ArC), 138.0 (ArC), 137.9 (ArC), 133.6 (ArC), 129.9 (ArCH), 
129.4 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.8 (ArCH), 
127.73 (ArCH), 127.69 (ArCH), 127.6 (ArCH), 127.6 (ArCH), 87.7 (C1), 86.4 (C2), 85.1 
(C7), 82.5 (C6), 73.3 (OCH2Ph), 71.94 (OCH2Ph), 71.90 (OCH2Ph), 71.7 (C1՛), 71.5 (C7a), 
68.7 (C3), 66.5 (C5), 19.3 (C1՛՛). LRESIMS m/z 594 (100%) [M+H]+. HRMS (ESI-TOF) 
m/z: [M+H]
+ 
Calcd for C37H40NO6 594.2856; Found 594.2874. 41 Rf 0.38 (1:1 diethyl 
ether/hexane). [α]
+54.7 (c 1.00, CHCl3). IR υmax (cm
-1
): 3369, 3097, 2958, 1608, 1539, 
1137, 1023, 699, 583. 
1
H NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.5 Hz, o-Bz), 7.56 
(1H, t, J = 7.5 Hz, p-Bz), 7.43 (2H, t, J = 7.6 Hz, m-Bz), 7.38 – 7.23 (15H, m, ArH), 5.31 
(1H, d, J = 4.0 Hz, H6), 4.62 – 4.51 (3H, m, OCH2Ph), 4.53 – 4.43 (3H, m, OCH2Ph), 4.30 
(1H, d, J = 2.6 Hz, H1), 4.22 (1H, d, J = 2.4 Hz, H2), 4.10 (1H, t, J = 6.1 Hz, H7), 3.98 (1H, 
dd, J = 4.6, 2.2 Hz, H7a), 3.56 (1H, t, J = 9.0 Hz, H1՛), 3.52 – 3.38 (3H, m, OH, H1՛, H5), 
3.30 (1H, ddd, J = 8.6, 5.9, 2.4 Hz, H3), 1.15 (3H, d, J = 6.5 Hz, H1՛՛). 13C NMR (125 MHz, 
CDCl3) δ 165.9 (CO), 138.4 (ArC), 137.9 (ArC), 137.0 (ArC), 133.1 (ArC), 129.8 (ArCH), 
128.6 (ArCH), 128.43 (ArCH), 128.36 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 
127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 84.9 (C2), 83.2 (C6), 82.3 (C1), 
75.4 (C7), 73.3 (OCH2Ph), 73.2 (C7a), 72.1 (OCH2Ph), 72.0 (C1՛), 71.7 (OCH2Ph), 69.8 
(C3), 62.5 (C5), 16.1 (C1՛՛). LRESIMS m/z 594 (100%) [M+H]+. HRMS (ESI-TOF) m/z: 
[M+H]
+ 





 Compound 42 was synthesized from 40 
(23 mg, 0.0387 mmol) using the general method for O-benzoyl deprotection. Purification by 
FCC (5:95 MeOH/CH2Cl2) returned the product as colorless crystals (15 mg, 79%). Rf 0.28 
(5:95 MeOH/CH2Cl2). [α]
+14.6 (c 1.00, CHCl3). IR υmax (cm
-1
): 3370, 3078, 2968, 2930, 




H NMR (500 MHz, CDCl3) δ 7.33 – 
7.21 (15H, m, ArH), 4.61 – 4.41 (6H, m, OCH2Ph), 4.10 (1H, t, J = 3.6 Hz, H2), 4.07 (1H, t, 
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J = 3.6 Hz, H1), 3.97 (1H, t, J = 7.5 Hz, H7), 3.68 (1H, t, J = 8.1 Hz, H6), 3.48 – 3.40 (3H, 
m, H1՛ and H7a), 3.23 (1H, dt, J = 9.8, 4.5 Hz, H3), 3.06 (2H, s, OH), 2.93 (1H, dq, J = 12.6, 
6.4 Hz, H5), 1.17 (3H, d, J = 6.2 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 
138.01 (ArC), 138.00 (ArC), 128.42 (ArCH), 128.40 (ArCH), 128.3 (ArCH), 127.8 (ArCH), 
127.69 (ArCH), 127.67 (ArCH), 127.5 (ArCH), 87.2 (C1), 86.0 (C2), 83.1 (C6), 80.2 (C7), 
73.2 (OCH2Ph), 72.3 (C7a), 71.9 (OCH2Ph), 71.6 (OCH2Ph), 71.3 (C1՛), 69.2 (C3), 65.3 
(C5), 19.0 (C1՛՛). LRESIMS m/z 490 [M+H]+. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for 
C30H36NO5 490.2593; Found 490.2617. 
 
(1R,2R,3S,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-3-
methylhexahydro-1H-pyrrolizine-1,2-diol (43). Compound 43 was synthesized from 41 (8 
mg, 0.0135 mmol) using the general method for O-benzoyl deprotection. The crude brown oil 
was purified by FCC (5:95 MeOH/CH2Cl2) to give the product as a clear yellow oil (6 mg, 
90%). Rf 0.15 (5:95 MeOH/CH2Cl2). [α]
+17.4 (c 1.00, CHCl3). IR υmax (cm
-1
): 3387, 
3049, 2922, 1643, 1428, 1354, 1067, 697. 
1
H NMR (500 MHz, CDCl3) δ 7.53 – 7.05 (15H, 
m, ArH), 4.64 – 4.40 (6H, m, OCH2Ph), 4.32 (1H, s, H1), 4.22 – 4.14 (2H, m, H2 and H7), 
4.09 (1H, s, H7a), 3.94 (1H, s, H6), 3.61 – 3.55 (2H, m, H1՛), 3.37 – 3.32 (1H, m, H3), 3.29 
(1H, bs, H5), 1.23 (3H, d, J = 6.5 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 138.1 (ArC), 
137.7 (ArC), 136.7 (ArC), 128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 
(ArCH), 127.9 (ArCH), 127.74 (ArCH), 127.70 (ArCH), 127.66 (ArCH), 84.8 (C2), 81.4 
(C1), 81.2 (C6), 76.8 (C7a), 73.3 (OCH2Ph), 72.9 (C7), 72.4 (OCH2Ph), 72.0 (OCH2Ph), 70.6 
(C1՛), 69.3 (C3), 64.2 (C5), 14.0 (H1՛՛). LRESIMS m/z 490 [M+H]+. HRMS (ESI-TOF) m/z: 
[M+H]
+
 Calcd for C30H36NO5 490.2593; Found 490.2613. 
 
(1R,2R,3R,5S,6S,7S,7aR)-3-(hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetraol [Originally proposed structure of (+)-hyacinthacine C5] (6).
15,22,23
 (+)-
Hyacinthacine C5 6 was synthesized by the general method of O-benzyl deprotection from 42 
(20 mg, 0.0408 mmol). The crude product was filtered through a pad of celite and washed 
with additional MeOH (6 mL). The combined filtrates were concentrated in vacuo returning a 
yellow film. The title compound was then isolated, through basic ion-exchange 
chromatography followed by concentration in vacuo, as a colorless film (9 mg, 99%). 
[α]
+9.5 (c 1.00, H2O). IR υmax (cm
-1
): 3302, 2952, 2926, 1603, 1545, 1212, 1079, 694. 
1
H 
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NMR (500 MHz, D2O) δ 4.15 (1H, t, J = 7.0 Hz, H1), 4.11 (1H, t, J = 7.1 Hz, H7), 3.96 (1H, 
t, J = 7.0 Hz, H2), 3.74 – 3.61 (3H, m, H6, H8), 3.05 (1H, t, J = 6.8 Hz, H7a), 2.96 – 2.87 
(2H, m, H5, H3), 1.20 (3H, d, J = 6.2 Hz, H9). 
13
C NMR (125 MHz, D2O) δ 82.9 (C6), 80.2 
(C1), 79.6 (C7), 79.3 (C2), 71.2 (C7a), 71.1 (C5), 66.0 (C3), 62.9 (C8), 17.8 (C9). LRESIMS 
m/z 220 [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 




pyrrolizine-1,2,6,7-tetraol [(+)-5-epi-hyacinthacine C5] (12).
23
 (+)-5-Epi-hyacinthacine C5 
12 was synthesized by the general method of O-benzyl deprotection from 43 (6 mg, 0.0123 
mmol). The crude product was filtered through a pad of celite and washed with additional 
MeOH (6 mL). The combined filtrates were concentrated in vacuo returning a yellow film. 
The title compound was then isolated, through basic ion-exchange chromatography followed 
by concentration in vacuo, as a white solid (2 mg, 78%). [α]
 +10.3 (c 1.00, H2O). IR υmax 
(cm
-1
): 3298, 2963, 1593, 1546, 1273, 1086, 699. 
1
H NMR (500 MHz, D2O) δ 4.28 (1H, t, J 
= 7.5 Hz, H1), 4.21 (1H, dd, J = 4.7, 2.4 Hz, H7), 4.13 (1H, dd, J = 4.2, 2.4 Hz, H6), 3.96 
(1H, t, J = 8.4 Hz, H2), 3.78 (1H, dd, J = 12.3, 4.0 Hz, H8), 3.68 (1H, dd, J = 12.0, 4.6 Hz, 
H8), 3.46 (1H, dd, J = 7.2, 4.6 Hz, H7a), 3.14 (1H, q, J = 6.1, 4.9, 4.3 Hz, H5), 2.78 (1H, dd, 
J = 9.3, 4.6 Hz, H3), 1.17 (3H, d, J = 6.9 Hz, H9). 
13
C NMR (125 MHz, D2O) δ 82.2 (C6), 
81.2 (C2), 76.8 (C7), 75.6 (C1), 73.1 (C3), 71.6 (C7a), 65.2 (C5), 64.2 (C8), 16.5 (C9). 
LRESIMS m/z 220 (100%) [M+H]
+
. HRMS (ESI-TOF) m/z: [M+H]
+ 
Calcd for C9H18NO5 
220.1185; Found 220.1175. 
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